Immune cell organoid co-cultures
Patent Information
- Application Number
- JP2023219225
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-12-21
- Filing Date
- 2023-12-26
- Publication Date
- 2024-11-11
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current in vitro systems for investigating diseases like cancer and immune diseases lack efficiency, accuracy, and cost-effectiveness, and do not accurately replicate physiological functions, particularly due to the absence of immune cells in organoid cultures, which are limited to epithelial cells and do not represent the complexity of in vivo tissue systems.
Development of organoid co-cultures that include immune cells, specifically tumoroids and immune cells, to create systems that accurately replicate patient physiology and investigate treatment regimens, using methods such as co-culturing tumoroids with immune cells and detecting changes indicative of candidate agent suitability through assays like cell viability and gene expression analysis.
The co-culture systems provide a high-throughput method to identify suitable therapeutic agents by detecting changes in tumoroid co-cultures, enhancing the accuracy and efficiency of drug screening and personalized medicine approaches.
Smart Images

Figure 00000053_0000 
Figure 00000053_0001 
Figure 00000053_0002
Abstract
Description
[Technical field]
[0001] All documents cited herein are incorporated by reference in their entirety.
[0002] Technical Field The present invention relates to organoid co-cultures and their use in investigating disease. [Background technology]
[0003] background Clinical research into the physiology underlying diseases such as cancer and immune disorders continues to be the cornerstone of medical advances, although in vitro systems for carrying out such investigations remain fundamental. Similarly, modern regimes for the treatment of such diseases are usually accompanied by rigorous testing systems during development to ensure efficacy and safety of the regime. Recent advances in these fields have increased the effectiveness of research and therapeutic testing systems, but improvements are needed in terms of system efficiency, accuracy, and cost-effectiveness. An ideal testing system would accurately reproduce the physiology of a patient or patient population at the biochemical, cellular, tissue, organ, and organism levels, while not requiring direct testing on patients and minimizing the use of patient samples. A variety of different therapeutic agents and time scales must be accommodated in one system.
[0004] In vitro models are required for "screening" candidate compounds to identify new strategies aimed at investigating and treating cancer and immune diseases at a population level. Furthermore, there is increasing interest in "personalized medicine," where in vitro models can be used to test (sometimes previously approved) strategies in subgroups of patients with specific characteristics, or even in samples from a single patient, to determine the optimal strategy for that particular subgroup or patient.
[0005] The field of organoid technology is revolutionizing our understanding of developmental biology. Organoids are cellular structures obtained by proliferation of epithelial cells, consisting of tissue-specific cell types that self-organize through cell sorting and spatially restricted lineage commitment (Clevers, Cell. 2016 Jun 16;165(7):1586-1597). A limitation of organoid-based models in the prior art is that they contain only epithelial cells and therefore are not fully representative of in vivo tissue systems containing multiple cell types. In particular, human "co-cultures" of cancer organoids ("tumouroids") and immune cells have not been described, and certainly not when cancer and immune cells are obtained from the same patient. Immune cells improve the accuracy of organoids as a test system, recapitulating the patient's physiology and ensuring that the immune system is represented in the test system.
[0006] Although previous attempts to understand the spatiotemporal behavior of intraepithelial lymphocytes (IELs) with intestinal epithelial cells have demonstrated co-culture of mouse IELs with mouse intestinal epithelial organoids - Nozaki et al. (J Gastroenterol. 2016 Mar;51(3):206-13 (Non-Patent Document 2)) and Rogoz et al. (J Immunol Methods. 2015 Jun;421:89-95 (Non-Patent Document 3)) - progress towards the development of human organoid co-cultures and their application in cancer investigation and treatment has not been reported. So-called "tumoroids" have been prepared from samples derived from colorectal cancer patients (Drost et al., Nature. 2015 May 7;521(7550):43-7 (Non-Patent Document 4); van de Wetering et al., Cell. 2015 May 7;161(4):933-45 (Non-Patent Document 5)), but have not been co-cultured with immune cells to investigate therapeutic strategies for cancer.
[0007] Improved methods for preparing organoid and tumoroid cocultures, as well as methods for using these cocultures in drug screening, are needed, particularly systems that can exploit interactions between disease and immune cells to investigate an increasing number of drugs with high-throughput capabilities. [Prior art documents] [Non-patent literature]
[0008] [Non-Patent Document 1] Clevers, Cell. 2016 Jun 16;165(7):1586-1597 [Non-Patent Document 2] J Gastroenterol. 2016 Mar;51(3):206-13 [Non-Patent Document 3] J Immunol Methods. 2015 Jun;421:89-95 [Non-Patent Document 4] Drost et al., Nature. 2015 May 7;521(7550):43-7 [Non-Patent Document 5] van de Wetering et al., Cell. 2015 May 7;161(4):933-45 Summary of the Invention
[0009] The present inventors have developed organoid co-cultures that are useful for the research related to diseases such as cancer and immune disease, including identifying the appropriate treatment for such diseases.In some embodiments, this includes the preparation of organoid and immune cell, particularly disease organoid (such as tumoroid) and immune cell co-cultures, which can be exposed to candidate agents to treat disease and detect any changes to identify suitable candidate agents.
[0010] Thus, the present invention provides, inter alia, a method for identifying an agent suitable for treating cancer, the method comprising: contacting the tumouroid co-culture with one or more candidate agents, wherein the tumouroid co-culture comprises immune cells and at least one tumouroid; detecting the presence or absence of one or more alterations in the tumoroid co-cultures that indicate the suitability of a candidate agent for the treatment of cancer; and Identifying a candidate agent as suitable for treating cancer if the presence or absence of one or more of said alterations is detected in said tumoroid co-cultures.
[0011] In some embodiments, the above method further comprises comparing the presence or absence of one or more changes in the tumoroid co-culture with a reference organoid or a reference tumoroid, and the method further comprises: contacting a reference organoid co-culture or a reference tumoroid co-culture with one or more candidate agents, wherein the reference organoid co-culture or the reference tumoroid co-culture comprises immune cells and at least one organoid or tumoroid; Detecting the presence or absence of one or more changes in the reference organoid co-culture or reference tumoroid co-culture that indicate the suitability of the candidate agent for the treatment of cancer.
[0012] The present invention further provides a method of identifying an agent suitable for treating an immune disease, the method comprising: contacting the organoid co-culture with one or more candidate agents, wherein the organoid co-culture comprises the diseased immune cells and at least one organoid; Detecting the presence or absence of one or more changes in the organoid co-culture that indicate the suitability of the candidate agent for treating an immune disease; and Identifying the candidate agent as suitable for treating an immune disease when the presence or absence of one or more of said changes is detected in the organoid co-culture.
[0013] In some embodiments, the above method further comprises comparing the presence or absence of one or more alterations in the organoid co-culture to reference immune cells (e.g., from a control patient lacking an immune disease), the method further comprising: contacting a reference organoid co-culture with one or more candidate agents, wherein the reference organoid co-culture comprises immune cells and at least one organoid; and Detecting the presence or absence of one or more changes in the reference organoid co-culture that indicate the suitability of the candidate agent for treating an immune disease.
[0014] Also provided is a method of testing a CAR-T immunotherapy, a TCR transgenic T cell, a neoantigen, or a checkpoint inhibitor for efficacy and / or safety when used to treat an epithelial cancer, the method comprising: Optionally, providing tumor epithelial cells, normal epithelial cells, and immune cells from the same patient; growing tumor epithelial cells in a tumorigenic culture medium to form tumorigenic cells, and culturing the tumorigenic cells with immune cells in a tumorigenic co-culture medium containing interleukin to form tumorigenic co-cultures; Proliferating normal epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form a reference organoid co-culture; contacting the organoid co-culture and the reference organoid co-culture with a CAR-T immunotherapy, a TCR transgenic T cell, a neoantigen, or a checkpoint inhibitor; Detecting the presence or absence of one or more alterations in the tumoroid co-culture and the reference organoid co-culture, wherein the presence or absence of the one or more alterations indicates the efficacy and / or safety of the CAR-T immunotherapy, TCR transgenic T cells, neoantigens, or checkpoint inhibitors; and Comparing organoid co-cultures and reference organoid co-cultures.
[0015] Also provided is a method of testing a candidate compound for efficacy and / or safety for use in treating epithelial cancer, the method comprising: Optionally, providing tumor epithelial cells, normal epithelial cells, and immune cells from the same patient; growing tumor epithelial cells in a tumorigenic culture medium to form tumorigenic cells, and culturing the tumorigenic cells with immune cells in a tumorigenic co-culture medium containing interleukin to form tumorigenic co-cultures; Proliferating normal epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form a reference organoid co-culture; contacting the organoid co-culture and the reference organoid co-culture with a candidate compound; Detecting the presence or absence of one or more changes in the tumoroid co-culture and the reference organoid co-culture, wherein the presence or absence of one or more changes indicates the efficacy and / or safety of the candidate compound; and Comparing organoid co-cultures and reference organoid co-cultures.
[0016] Also provided is a method for preparing an organoid-immune cell co-culture, the method comprising: Optionally, culturing the epithelial cells in an organoid culture medium and in contact with an extracellular matrix to obtain organoids; Removing the extracellular matrix and organoid culture medium from the organoids; resuspending the organoids in immune cell culture medium supplemented with interleukins; preparing an immune cell suspension comprising immune cells, an immune cell culture medium supplemented with interleukin, and collagen at a concentration of at least 5-10% in the immune cell suspension; and Mixing the immune cell suspension containing the immune cells with the resuspended organoids.
[0017] Also provided is a method for preparing a tumorigenesis-immune cell co-culture, the method comprising: Optionally, culturing the tumor epithelial cells in a tumoroid culture medium and in contact with an extracellular matrix to obtain organoids; removing the extracellular matrix and the tumoroid culture medium from the tumoroids; resuspending the tumorigenesis cells in immune cell culture medium supplemented with interleukins; preparing an immune cell suspension comprising immune cells, an immune cell culture medium supplemented with interleukin, and collagen at a concentration of at least 5-10% in the immune cell suspension; and Mixing the immune cell suspension containing the immune cells with the resuspended tumoroids.
[0018] Also provided is a method of testing a therapeutic agent, the method comprising: contacting the organoid co-culture with one or more candidate agents, wherein the organoid co-culture comprises immune cells and at least one organoid; Detecting the presence or absence of one or more changes in the organoid co-culture that are indicative of therapeutic efficacy; and If the presence or absence of one or more of said changes is detected in the organoid co-culture, the candidate agent is identified as a therapeutic agent.
[0019] Also provided is an organoid co-culture obtainable or obtainable by the methods of the invention.
[0020] Also provided is a tumouroid co-culture obtainable or obtainable by the method of the invention.
[0021] Also provided are populations of organoids obtainable or obtainable by the methods of the invention.
[0022] There is also provided a population of tumouroids obtainable or obtainable by the methods of the invention.
[0023] Organoid co-culture media suitable for use in the methods of the invention are also provided.
[0024] Also provided is a tumoroid co-culture medium and an organoid co-culture medium suitable for use in the method of the present invention.Also provided is tumoroid or organoid in a medium containing interleukin, optionally wherein interleukin is selected from the group consisting of IL-2, IL-7 and IL-15.
[0025] The present invention also provides kits comprising the tumoroids, organoids, tumoroid co-cultures, or organoid co-cultures of the present invention. [The present invention 1001] 1. A method for identifying an agent suitable for treating cancer, comprising: contacting the tumouroid co-culture with one or more candidate agents, wherein the tumouroid co-culture comprises immune cells and at least one tumouroid; detecting the presence or absence of one or more alterations in the tumoroid co-cultures that indicate the suitability of a candidate agent for the treatment of cancer; and Identifying a candidate agent as suitable for treating cancer if the presence or absence of one or more of said alterations is detected in said tumoroid co-cultures. [The present invention 1002] The method of the present invention 1001, wherein the suitability for the treatment of cancer includes efficacy for the treatment of cancer and / or safety for the treatment of cancer. [The present invention 1003] Any of the aforementioned methods of the invention, wherein the one or more alterations are alterations in one or more cancer biomarkers. [The present invention 1004] Any of the methods of the present invention, wherein the one or more changes are selected from reduced cell viability, reduced cell proliferation, increased cell death, changes in cell or organoid size, changes in cell motility, changes in production of cytokines and cytotoxic molecules by co-cultured immune cells, dissociation or destruction of an intact / dense epithelial cell layer, and changes in expression of one or more genes. [The present invention 1005] Any of the preceding methods of the invention, wherein detecting comprises a cell proliferation assay, a viability assay, flow cytometry analysis, ELISA for IFN-γ, analysis of gene expression, and / or cell imaging. [The present invention 1006] Any of the methods of the above invention, wherein the one or more alterations is a reduction in cell viability, as detected, for example, by a CellTiter Glo Luminescent Cell Viability Assay kit (Promega), intracellular flow cytometry staining for active caspase 3 (BD), or positive staining of dead cells. [The present invention 1007] Any of the aforementioned methods of the invention, wherein the one or more changes is increased cell death, for example as detected by bright field imaging. [The present invention 1008] Any of the methods of the invention described above, preceded by one or more of the following steps: preparing at least one tumoroid by culturing tumor epithelial cells in tumoroid culture medium; preparing immune cells by isolating the immune cells from an impure immune sample and culturing the immune cells in an immune cell growth medium; and / or Preferably, a step of preparing a tumouroid co-culture by removing tumouroid culture medium from at least one tumouroid and mixing said at least one tumouroid with immune cells in tumouroid co-culture medium. [The present invention 1009] Any of the preceding methods of the invention comprising comparing the presence or absence of one or more changes in the tumoroid co-culture with a reference organoid or a reference tumoroid, and further comprising: contacting a reference organoid co-culture or a reference tumoroid co-culture with one or more candidate agents, wherein the reference organoid co-culture or the reference tumoroid co-culture comprises immune cells and at least one organoid or tumoroid; and Detecting the presence or absence of one or more changes in the reference organoid co-culture or reference tumoroid co-culture that indicate the suitability of the candidate agent for the treatment of cancer. [The present invention 1010] The method of the present invention 1009, wherein the candidate agent is identified as a suitable agent if the presence or absence of an alteration is detected in the tumoroid co-culture but not in the reference organoid co-culture or the reference tumoroid co-culture. [The present invention 1011] Any of the methods of claims 1009 to 1010, preceded by one or more of the following steps: Preparing at least one organoid by culturing normal epithelial cells in an organoid culture medium; preparing immune cells by isolating the immune cells from an impure immune sample and culturing the immune cells in an immune cell growth medium; and / or Preferably, a step of preparing a reference organoid co-culture or a reference tumouroid co-culture by removing the tumouroid culture medium from at least one tumouroid or at least one organoid and subsequently mixing at least one reference organoid or at least one reference organoid with immune cells in an organoid co-culture medium or a tumouroid co-culture medium; Optionally, the impure immune sample is a tumor sample, normal colon tissue, and / or peripheral blood. [The present invention 1012] The method of any of claims 1008 to 1011, wherein the normal epithelial cells are autologous with the tumor epithelial cells. [The present invention 1013] Any of the methods of 1009 to 1012, wherein a reference organoid co-culture or a reference tumoroid co-culture is used as a control, preferably as a negative control. [The present invention 1014] (i) a tumoroid co-culture medium and / or (ii) a reference organoid co-culture medium or a reference tumoroid co-culture medium, An extracellular matrix, preferably selected from collagen or any animal-derived or synthetic basement membrane matrix. Any of the methods 1008 to 1013 of the present invention. [The present invention 1015] The method of claim 1014, wherein the collagen is rat tail collagen I. [The present invention 1016] Any of the methods of the invention, wherein the co-culture comprises at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, or at least 10% collagen, preferably the co-culture comprises about 10% (v / v) collagen. [The present invention 1017] Any of the methods of claims 1008 to 1016, wherein (i) the tumoroid co-culture medium and / or (ii) the reference organoid co-culture medium or the reference tumoroid co-culture medium has a protein concentration of 0.15 mg / (ml Matrigel(registered trademark)) to 0.95 mg / (ml Matrigel(registered trademark)) for a Matrigel(registered trademark) concentration of 2% to 10%. [The present invention 1018] The tumoroid co-culture medium and / or organoid co-culture medium of any of 1008, 1011, or 1014 to 1017 of the present invention. [The present invention 1019] Any of the methods of the present invention, wherein the immune cells of the tumoroid co-culture and / or the reference organoid co-culture and / or the reference tumoroid co-culture have a motility of at least 40 μm / day, 60 μm / day, 80 μm / day, 100 μm / day, 120 μm / day, or 140 μm / day. [The present invention 1020] Any of the methods of the present invention, wherein at least 20%, at least 30%, at least 40%, or at least 50% of the immune cells in the tumoroid co-culture and / or the reference organoid co-culture and / or the reference tumoroid co-culture are able to migrate a distance of at least 200 μm, at least 250 μm, at least 300 μm, at least 350 μm, or at least 400 μm in 80 hours. [The present invention 1021] Any of the aforementioned methods of the present invention, wherein the immune cells remain active for at least 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, or 72 hours. [The present invention 1022] Any of the methods of the invention, wherein one or more candidate agents have a known suitability for the treatment of cancer, and the method further comprises identifying the one or more candidate agents as suitable agents for the treatment of cancer in a particular patient. [The present invention 1023] Any of the methods of claims 1009 to 1022, wherein both the tumoroid co-culture and the reference organoid co-culture or the reference tumoroid co-culture are derived from a particular patient. [The present invention 1024] The method of any of claims 1022-1023, further comprising treating the patient with a candidate agent identified as suitable for treating cancer in the particular patient. [The present invention 1025] Any of the preceding methods of the invention, wherein the one or more candidate agents are selected from one or more of the following therapeutic classes: immunotherapeutics, tumor-specific peptides, checkpoint inhibitors, alkylating agents, antimetabolites, metabolic agonists, metabolic antagonists, plant alkaloids, mitotic inhibitors, antitumor antibiotics, topoisomerase inhibitors, radiotherapeutics, chemotherapeutics, antibodies, photosensitizers, transplant stem cells, vaccines, cytotoxic agents, cytostatic agents, tyrosine kinase inhibitors, proteasome inhibitors, cytokines, interferons, interleukins, intercalating agents, targeted therapy agents, small molecule drugs, hormones, steroids, cellular therapeutic agents, viral vectors, and nucleic acid therapeutic agents. [The present invention 1026] Any of the methods of the invention described above, wherein the one or more candidate agents are selected from one or more of the following therapeutic classes: tumor-specific peptides, checkpoint inhibitors, chimeric antigen receptor (CAR)-T cell therapeutics, therapeutic TCR transgenic T cells, and neoantigens. [The present invention 1027] Any of the aforementioned methods of the invention, wherein one or more candidate agents are immunotherapeutic agents. [The present invention 1028] The method of the present invention 1027, wherein the immunotherapeutic agent is a chimeric antigen receptor (CAR)-T cell therapy, a therapeutic TCR transgenic T cell, or a neoantigen. [The present invention 1029] Any of the methods of claims 1001 to 1021, wherein one or more candidate agents have unknown suitability for treating cancer, and the method further comprises identifying a subset of the one or more candidate agents as suitable agents for treating cancer. [The present invention 1030] The method of any of claims 1001-1021 or 1029, wherein one or more candidate agents have known suitability for treating a first cancer and unknown suitability for treating a second cancer, and the method further comprises identifying a subset of the one or more candidate agents as suitable agents for treating the second cancer. [The present invention 1031] Any of the aforementioned methods of the present invention, wherein the cancer is an epithelial cancer. [The present invention 1032] Any of the aforementioned methods of the present invention, wherein the cancer is gastrointestinal cancer. [The present invention 1033] Any of the aforementioned methods of the present invention, wherein the cancer is colorectal cancer. [The present invention 1034] Any of the foregoing methods of the invention, wherein the cancer comprises one or below of stage II, grade II, or T2 N1 M0 cancer. [The present invention 1035] The method of any of claims 1008 to 1034, wherein the tumor epithelial cells and / or normal epithelial cells are obtained from a sample from a cancer patient. [The present invention 1036] The method according to any of claims 1008 to 1035, wherein the tumor epithelial cells and the normal epithelial cells are obtained from the same cancer patient, optionally from the same sample. [The present invention 1037] Any of the aforementioned methods of the invention, wherein the sample is a tissue biopsy. [The present invention 1038] Any of the foregoing methods of the invention, wherein tissue biopsies are taken from the resected colon and / or rectum of a colorectal cancer patient, from the ascites of a colorectal or ovarian cancer patient, and / or from the urine of a renal cancer patient. [The present invention 1039] Any of the methods of the invention, wherein the tumor epithelial cells and / or normal epithelial cells are selected from the group consisting of lung cells, liver cells, breast cells, skin cells, intestinal cells, crypt cells, rectal cells, pancreatic cells, endocrine cells, exocrine cells, ductal cells, kidney cells, adrenal cells, thyroid cells, pituitary cells, parathyroid cells, prostate cells, gastric cells, esophageal cells, ovarian cells, fallopian tube cells, or vaginal cells. [The present invention 1040] Any of the preceding methods of the invention, wherein the tumor epithelial cells and / or normal epithelial cells are intestinal cells, such as colorectal cells. [The present invention 1041] Any of the methods of the present invention, wherein the tumor epithelial cells and / or normal epithelial cells are epithelial stem cells, preferably characterized by Lgr5 expression. [The present invention 1042] Any of the above methods of the invention, wherein the immune cells comprise one or more cell types selected from the group consisting of intraepithelial lymphocytes (IELs), tumor infiltrating lymphocytes (TILs), peripheral blood mononuclear cells (PBMCs), peripheral blood lymphocytes (PBLs), T cells, and cytotoxic T lymphocytes (CTLs), αβ T cells, γδ T cells, B cells, NK cells, and mononuclear phagocytes. [The present invention 1043] Any of the aforementioned methods of the invention, wherein the immune cells are obtained from a sample from a cancer patient. [The present invention 1044] Any of the aforementioned methods of the invention, wherein the immune cells are obtained from a peripheral blood sample and / or a tissue biopsy. [The present invention 1045] Any of the preceding methods of the invention, wherein the peripheral blood lymphocytes (PBLs) and / or T cells are obtained from a peripheral blood sample. [The present invention 1046] Any of the aforementioned methods of the invention, wherein the tumor infiltrating lymphocytes (TILs) and / or intraepithelial lymphocytes (IELs) are obtained from a tumor or normal tissue biopsy, respectively. [The present invention 1047] Any of the aforementioned methods of the invention, wherein the immune cells are obtained from the same patient as the tumor epithelial cells and / or normal epithelial cells. [The present invention 1048] Any of the methods of the present invention, wherein the immune cells are allogeneic to the tumoroids and / or organoids, and optionally the immune cells and tumoroids and / or organoids are derived from either peripheral blood or tissue biopsy of a different patient or healthy control. [The present invention 1049] Any of the methods of the present invention, wherein the immune cells are HLA-matched to the tumoroids and / or organoids. [The present invention 1050] Any of the methods of the invention, wherein the immune cells persist in the immune cell expansion medium for at least 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, and 240 hours. [The present invention 1051] Any of the methods of the present invention, wherein at least one tumoroid and / or at least one organoid comprises or consists of autologous cells. [The present invention 1052] Any of the methods of the present invention, wherein at least one tumoroid and / or at least one organoid is separated into populations sharing one or more genotypic, phenotypic, and / or epigenetic markers prior to mixing with the immune cells. [The present invention 1053] Any of the methods of the present invention, wherein genotypic, phenotypic, and / or epigenetic markers contribute to the interaction between (i) at least one tumoroid and / or at least one organoid and (ii) immune cells. [The present invention 1054] Any of the preceding methods of the invention, wherein the populations share the presence or absence of an HLA haplotype, optionally the HLA haplotype is HLA-A2. [The present invention 1055] Any of the methods of the present invention, wherein at least one tumoroid or at least one organoid comprises or consists of mammalian cells, preferably human cells. [The present invention 1056] Any of the methods of the present invention, wherein at least one tumoroid co-culture or at least one organoid co-culture is cultured in immune cell growth medium or in a 50:50 (v / v) mixture of immune cell growth medium and organoid culture medium or tumoroid culture medium (respectively). [The present invention 1057] Any of the methods of the present invention, wherein the tumouroid co-culture is maintained in tumouroid co-culture medium, or the reference organoid co-culture or the reference tumouroid co-culture is maintained in organoid co-culture medium, for at least 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, and 240 hours. [The present invention 1058] A tumoroid or organoid as in any of the above aspects of the present invention, wherein the tumoroid or organoid is in a medium containing an interleukin, and optionally the interleukin is selected from the group consisting of IL-2, IL-7, and IL-15. [The present invention 1059] A population of tumoroids or organoids prepared according to any of the methods of the present invention. [The present invention 1060] A tumoroid co-culture and / or a reference organoid co-culture as described above in any of the present invention. [The present invention 1061] Any of the methods of the present invention, wherein the organoid culture medium comprises one or more (or preferably all) of a basal medium (such as Advanced DMEM / F12 medium, Gibco), a Wnt ligand (such as Wnt-3a), a Wnt agonist (such as any one of Rspondin 1-4), a BMP inhibitor (such as Noggin), EGF, and a TGF-β inhibitor (such as A83-01, Tocris), and optionally further comprises one or more (or all) of a p38 MAPK inhibitor, gastrin, nicotinamide, prostaglandin E, N-acetylcysteine, B27, and / or an antibacterial agent (such as Primocin). [The present invention 1062] Any of the methods of the invention, wherein the tumoroid culture medium comprises one or more (or preferably all) of a basal medium (such as Advanced DMEM / F12 medium, Gibco), a Wnt agonist (such as any one of Rspondin 1-4), a BMP inhibitor (such as Noggin), EGF, and a TGF-β inhibitor (such as A83-01, Tocris), and optionally further comprises one or more (or all) of a p38 MAPK inhibitor, gastrin, nicotinamide, prostaglandin E, N-acetylcysteine, B27, and / or an antibacterial agent (such as Primocin), and optionally the tumoroid culture medium further comprises a Wnt ligand (such as Wnt-3a). [The present invention 1063] Any of the methods of the invention, wherein the immune cell growth medium comprises IL-2, optionally at a concentration of 2000-6000 IU / mL, and optionally further comprises IL-7 and / or IL-15. [The present invention 1064] Any of the aforementioned methods of the invention, wherein the immune cell growth medium further comprises RPMI medium (e.g., RPMI 1640, Gibco), optionally supplemented with penicillin / streptomycin and / or serum (e.g., 5% human AB serum, Sigma-Aldrich). [The present invention 1065] Any of the methods of the present invention, wherein the tumoroid co-culture medium and / or the organoid co-culture medium contains IL-2, optionally at a concentration of 100 to 200 IU / mL. [The present invention 1066] 1. A method of testing a CAR-T immunotherapy, a TCR transgenic T cell, a neoantigen, or a checkpoint inhibitor for efficacy and / or safety when used to treat epithelial cancer, the method comprising: Optionally, providing tumor epithelial cells, normal epithelial cells, and immune cells from the same patient; growing tumor epithelial cells in a tumorigenic culture medium to form tumorigenic cells, and culturing the tumorigenic cells with immune cells in a tumorigenic co-culture medium containing interleukin to form tumorigenic co-cultures; Proliferating normal epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form a reference organoid co-culture; contacting the organoid co-culture and the reference organoid co-culture with a CAR-T immunotherapy, a TCR transgenic T cell, a neoantigen, or a checkpoint inhibitor; Detecting the presence or absence of one or more alterations in the tumoroid co-culture and the reference organoid co-culture, wherein the presence or absence of the one or more alterations indicates the efficacy and / or safety of the CAR-T immunotherapy, TCR transgenic T cells, neoantigens, or checkpoint inhibitors; and Comparing organoid co-cultures and reference organoid co-cultures. [The present invention 1067] 1. A method for testing a candidate compound for efficacy and / or safety for use in treating epithelial cancer, the method comprising: Optionally, providing tumor epithelial cells, normal epithelial cells, and immune cells from the same patient; growing tumor epithelial cells in a tumorigenic culture medium to form tumorigenic cells, and culturing the tumorigenic cells with immune cells in a tumorigenic co-culture medium containing interleukin to form tumorigenic co-cultures; Proliferating normal epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form a reference organoid co-culture; contacting the organoid co-culture and the reference organoid co-culture with a candidate compound; Detecting the presence or absence of one or more changes in the tumoroid co-culture and the reference organoid co-culture, wherein the presence or absence of one or more changes indicates the efficacy and / or safety of the candidate compound; and Comparing organoid co-cultures and reference organoid co-cultures. [The present invention 1068] 1. A method for preparing an organoid-immune cell co-culture, comprising: Optionally, culturing the epithelial cells in an organoid culture medium and in contact with an extracellular matrix to obtain organoids; Removing the extracellular matrix and organoid culture medium from the organoids; resuspending the organoids in immune cell culture medium supplemented with interleukins; preparing an immune cell suspension comprising immune cells, an immune cell culture medium supplemented with interleukin, and collagen at a concentration of at least 5-10% in the immune cell suspension; and Mixing the immune cell suspension containing the immune cells with the resuspended organoids. [The present invention 1069] 1. A method for preparing a tumorigenesis-immune cell co-culture, comprising: Optionally, culturing the tumor epithelial cells in a tumoroid culture medium and in contact with an extracellular matrix to obtain organoids; removing the extracellular matrix and the tumoroid culture medium from the tumoroids; resuspending the tumorigenesis cells in immune cell culture medium supplemented with interleukins; preparing an immune cell suspension comprising immune cells, an immune cell culture medium supplemented with interleukin, and collagen at a concentration of at least 5-10% in the immune cell suspension; and Mixing the immune cell suspension containing the immune cells with the resuspended tumoroids. [The present invention 1070] The method of any one of claims 1068 to 1069, wherein the collagen is rat tail collagen. [The present invention 1071] The method according to any one of claims 1068 to 1070, wherein the immune cell medium is RPMI1640 (Gibco). [The present invention 1072] The method according to any one of claims 1068 to 1071, wherein the immune cell is a T cell. [The present invention 1073] The method according to any of claims 1068 to 1072, wherein the epithelial cells and the immune cells are obtained from the same subject, optionally from the same sample. [The present invention 1074] The method according to any one of claims 1068 to 1072, wherein the epithelial cells and immune cells are human cells. [The present invention 1075] An organoid-immune cell co-culture obtained by any one of the methods of the present invention 1068 or 1070 to 1074. [The present invention 1076] A tumorigenesis-immune cell co-culture obtained by any one of the methods of the present invention Nos. 1069 to 1074. [The present invention 1077] 1. A method for testing a therapeutic agent, comprising: contacting the organoid co-culture with one or more candidate agents, wherein the organoid co-culture comprises immune cells and at least one organoid; Detecting the presence or absence of one or more changes in the organoid co-culture that are indicative of therapeutic efficacy; and If the presence or absence of one or more of said changes is detected in the organoid co-culture, the candidate agent is identified as a therapeutic agent. [The present invention 1078] The method of the present invention 1077, wherein the therapeutic agent is suitable for treating an immune disease, optionally wherein the immune disease affects lung and / or intestinal tissue, for example, the immune disease is selected from the group consisting of irritable bowel disease (IBD), ulcerative colitis (UC), chronic obstructive pulmonary disease (COPD), and asthma. [Brief description of the drawings]
[0026] [Figure 1A]Derivation of organoids, tumoroids, and T cells from primary patient tissues. Figure 1A: Schematic of the procedure. Biopsies of normal colon mucosa and tumor tissue are taken from the resected colon and / or rectum of colorectal cancer patients. Peripheral blood is also collected during surgery. Normal colon mucosa is treated with EDTA to liberate crypts for derivation of normal colon organoids and further digested to create single cell suspensions containing intraepithelial lymphocytes (IELs) for T cell cultures. Tumor tissue is digested to create single cell suspensions containing epithelial tumor cells for derivation of tumoroids and tumor infiltrating lymphocytes (TILs) for T cell cultures. Peripheral blood is processed to purify peripheral blood lymphocytes (PBLs) and peripheral blood mononuclear cells enriched for T cells. Primary analysis is performed by T cell receptor (TCR) sequencing and immunophenotyping of T cells and single cell messenger RNA (mRNA) sequencing of cells present in the single cell suspensions of normal colonic and tumor epithelium. Organoid cultures are analyzed using whole genome sequencing, mRNA sequencing, and peptidome profiling. FIG. 1 is further described in Example 1. [Figure 1B] Derivation of organoids, tumouroids, and T cells from primary patient tissue. Figure 1B: Representative brightfield images of normal colon organoids and tumouroids derived from patient samples. Colonic crypts were embedded in basement membrane extract (BME) and cultured in medium containing R-spondin-1, noggin, Wnt3A-conditioned medium, vitamin A-free B27 supplement, nicotinamide, N-acetylcysteine, EGF, TGF-β inhibitor A-83-01, gastrin, p38 MAPK inhibitor SB202190, and prostaglandin E2. Normal colon organoids developed within 1 week and were passaged weekly thereafter (top panel). Single cell suspensions from colorectal cancer samples were embedded in basement membrane extract (BME) and cultured in medium containing R-spondin-1, Noggin conditioned medium, Vitamin A-free B27 supplement, nicotinamide, N-acetylcysteine, EGF, TGF-β inhibitor A-83-01, gastrin, p38 MAPK inhibitor SB202190, and prostaglandin E2. Tumoroids formed within one week and were passaged weekly thereafter (lower panel). Figure 1 is further described in Example 1. [Figure 1C] Derivation of organoids, tumoroids, and T cells from primary patient tissues. Figure 1C: Representative brightfield images of clonal expansion of intraepithelial lymphocytes (IEL) and tumor infiltrating lymphocytes (TIL) derived from patient samples (left panel). Flow cytometry analysis shows robust expansion of CD4+ T helper (Th) cells and CD8+ cytotoxic T cells (CTL). Single cell suspensions from normal colon mucosa or colorectal cancer tissue were maintained in T cell medium containing interleukin-2 (IL-2). Clonal expansion of T cells was noticeable within 1-2 weeks (left panel). Figure 1 is further described in Example 1. [Diagram 2] Proof-of-principle co-culture of normal colon organoids and allogeneic CD3+ T cells in a drop of basement membrane extract (BME). Figure 2A: Schematic of the procedure. Normal colon organoids were released from the BME drop using Cell Recovery Solution and washed with complete Advanced DMEM / F12. Expanded CD3+ T cells were harvested from the culture and labeled with green dye (Vybrant CFDA SE Cell Tracer). Colon organoids and labeled T cells were mixed in human colon organoid medium and embedded into the BME drop. Co-cultures were maintained for 60 hours in human colon organoid medium with IL-2. Co-cultures were released from the BME using Cell Recovery Solution and fixed in 4% paraformaldehyde. Fixed whole tissue specimens were stained with phalloidin to mark polymerized actin and with DAPI to label nuclei. Whole tissue specimens were mounted on slides in ProLong Gold antifade mounting medium and imaged on a Leica SP8X confocal microscope. Figure 2B: Maximum projection of z-stack images of colonic organoid co-culture. F-actin in organoids is labeled in dark gray, and T cells are labeled in light gray. The inset in the right panel shows T cells infiltrating the colonic epithelium. Figure 2C: Three-dimensional reconstruction of normal colonic organoids and T cells. Figure 2 is further described in Example 8. [Diagram 3]Live imaging of tumouroid co-cultures to assess optimal motility of T cells. Figure 3A: Schematic of the procedure. Tumoroids were released from BME droplets using Cell Recovery Solution and washed with complete Advanced DMEM / F12. Allogeneic CD8+ T cells isolated from peripheral blood samples were labeled with green dye (Vybrant CFDA SE Cell Tracer). Tumoroids and T cells were mixed with human colon organoid medium containing IL-2 and either 10% BME or rat tail collagen I and live imaged for 80 h on a Leica SP8X confocal microscope equipped with a live imaging chamber at 37 °C and 5% CO2 atmosphere. Figure 3B: Representative composite image of tumouroid co-cultures. Bright field and green fluorescent channels were merged into the generated composite image. T cell migration paths were tracked using Imaris software. Figure 3C. Quantification of T cell trajectory length in both conditions shows significantly longer trajectory paths of T cells co-cultured in 10% collagen compared to 10% BME. FIG. 3 is described in more detail in Example 10. [Figure 4A] Production of clonal tumoroids positive and negative for human leukocyte antigen (HLA) type A2. Figure 4A: Schematic of the procedure. Tumoroids were dissociated into single cells using TrypLE enzyme digestion. Single cells were stained with anti-HLA-A2 antibody and purified based on anti-HLA-A2 immunoreactivity. HLA-A2+ve and HLA-A2-ve tumor cells were embedded and maintained to produce tumoroids. Figure 4 is further described in Example 11. [Figure 4B] Production of clonal tumoroids positive and negative for A2 human leukocyte antigen (HLA). Figure 4B: Flow cytometry analysis showing the establishment of pure HLA-A2+ve or HLA-A2-ve tumoroid lines. Controls are HLA-A2+ve JY cell lines and normal colon organoid lines derived from the same patient samples as HLA-A2+ve or HLA-A2-ve tumoroid lines. Figure 4 is further described in Example 11. [Diagram 5]Killing assay for anti-tumoroid reactivity of antigen-experienced T cells. Figure 5A: Schematic of the procedure. HLA-A2+ve or HLA-A2-ve tumoroids were pulsed with HLA-A2-restricted Wilms' tumor 1 (WT1) peptide for 2 hours. TCR transgenic CD8+ T cells harboring WT1 peptide-specific TCR were then co-cultured with HLA-A2+ve or HLA-A2-ve tumoroids pulsed with WT1 peptide for 48 hours. Figure 5B: Representative brightfield images of the co-culture after 48 hours showing significant death of HLA-A2+ve tumoroids pulsed with WT1 peptide alone. All other conditions, i.e. HLA-A2+ve or HLA-A2-ve tumoroids not pulsed with WT1 peptide, and HLA-A2-ve tumoroids pulsed with WT1 peptide, show normal growth. Figure 5 is explained in more detail in Example 12. [Figure 6] Cell viability assay for anti-tumoroid reactivity of antigen-experienced T cells with and without checkpoint inhibition. Figure 6A: Schematic of procedure. Co-cultures were performed as described for Figure 5A, but for 12 hours, and incubated with and without anti-PD1 checkpoint inhibitors. Cell viability assays were performed using the CellTiter Glo Luminescent Cell Viability Assay kit (Promega) according to the manufacturer's instructions. Figure 6B: Tumoroid cell viability normalized to no peptide control. Figure 6 is described in more detail in Example 13. [Figure 7]Assay to determine the differential effect on T cell activation by organoid / tumoroid co-culture. Figure 7A: Schematic of procedure. Tumoroids were released from Matrigel® droplets using Dispase and subsequently passed through 70 μm and 20 μm filters. Organoids were retrieved from the 20 μm filter, counted and plated. Tumoroids and T cells were mixed with human colon organoid medium containing RPMI, IL-2 and 5% Matrigel® and incubated at 37°C and 5% CO2 atmosphere. After 24 hours of incubation, organoids were imaged using a bright field inverted microscope. Figure 7B: Representative image of tumoroid co-culture. Figure 7C: Representative image of organoid co-culture. Figure 7D: Quantified IFN-γ levels of co-culture. Figure 7 is further described in Example 14. [Figure 8] Live imaging of tumouroid co-cultures to assess association and cell killing capacity. Figure 8A: Schematic of the procedure. Tumoroids were released from Matrigel® droplets using Dispase and subsequently passed through 70 μm and 20 μm filters. Organoids were retrieved from the 20 μm filters, counted and plated. Cultured T cells were labeled with far-red dye (CellVue Claret). Tumoroids and T cells were mixed with human colon organoid medium containing RPMI, IL-2 and 5% Matrigel® and live imaged for 68 hours on a Leica SP8X confocal microscope equipped with a live imaging chamber at 37°C and 5% CO2 atmosphere. Figure 8B: Representative composite image of tumouroid and non-targeted T cell co-cultures. Bright field and far-red fluorescent channels were merged into the generated composite image. Figure 8C: Representative composite image of tumouroid and targeted T cell co-cultures. Bright field and far-red fluorescent channels were merged into the generated composite image. FIG. 8 is further described in Example 15. [Figure 9A]CRC organoids express immune-modulating molecules. Normal colon and CRC organoid lines were generated in a patient-specific manner, and RNA was extracted and analyzed using Affymetrix single transcript microarrays. Figure 9A: Mean gene expression of different immune-modulating substances in normal colon and CRC organoid lines; ns, not significant; *, p<0.05. [Figure 9B] CRC organoids express immune-modulating molecules. Normal colon and CRC organoid lines were produced in a patient-specific manner, and RNA was extracted and analyzed using Affymetrix single transcript microarrays. Figure 9B: Hierarchical clustering of individual normal colon and CRC organoid lines in the "living biobank" showing gene expression of selected immune-modulating substances. The color gradient represents the z-score of each row (gene transcript). [Figure 9C] CRC organoids express immune-modulatory molecules. Normal colon and CRC organoid lines were produced in a patient-specific manner, and RNA was extracted and analyzed using Affymetrix single-transcript microarrays. Figure 9C: Human colon organoid lines genetically engineered to carry one or more mutations found in CRC. Expression levels of CD274 (PD-L1) in organoid lines (n=2) at steady state (Ctrl) and upon 20 ng / mL recombinant human IFN-γ stimulation, assessed by quantitative PCR. A, APCKO / KO; ND, not detected; K, KRASG12D / +: P, P53KO / KO; S, SMAD4KO / KO; WT, wild type. [Figure 9D]CRC organoids express immune-modulating molecules. Normal colon and CRC organoid lines were produced in a patient-specific manner, and RNA was extracted and analyzed using Affymetrix single-transcript microarrays. Figure 9D: Human colon organoid lines genetically engineered to carry one or more mutations found in CRC. Expression levels of CD274 (PD-L1) in organoid lines (n=2) at steady state (Ctrl) and upon 20 ng / mL recombinant human IFN-γ stimulation as assessed by flow cytometry. A, APCKO / KO; ND, not detected; K, KRASG12D / +: P, P53KO / KO; S, SMAD4KO / KO; WT, wild type. [Figure 10] HLA-A2 expression in clonally expanded HLA-A2+ and HLA-A2- CRC organoid lines. The figure shows representative plots of multiple replicate experiments. Flow cytometry analysis of HLA-A2 expression in normal (left panel), HLA-A2+ CRC (middle panel), and HLA-A2- CRC (right panel) lines with and without stimulation with 20 ng / mL recombinant human IFN-γ. [Figure 11A] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11A: Experimental concept. [Figure 11B] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11B: Flow cytometric analysis of HLA-A2 expression in cloned HLA-A2+ and HLA-A2- lines. [Figure 11C] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11C: Brightfield image of CRC organoids co-cultured with WT1 peptide-specific T cell receptor-specific transgenic T cells for 48 h; scale bar: 1 mm. [Figure 11D]CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11D: Images showing peptide-pulsed HLA-A2+ CRC organoids at the beginning and end of co-culture with the indicated peptide-specific T cells; scale bar: 70 μm. [Figure 11E] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11E: IFN-γ production by WT1 (top) and EBV (bottom) peptide-specific T cells measured by ELISA in supernatants collected after 18 h of co-culture with HLA-A2+ CRC organoids pulsed with the indicated peptides. [Figure 11F] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11F: Live cell imaging stills from an 18-hour co-culture experiment with EBV peptide-pulsed HLA-A2+ CRC organoids co-cultured with an EBV-specific T cell clone. [Figure 11G] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11G: Quantification of CRC organoid killing by specific T cells. Graphs are representative of multiple replicate experiments using either EBV peptide and EBV T cells or WT1 peptide and WT1 T cells co-cultures. [Figure 11H] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11H: Representative projection images of T cells (blue) infiltrating peptide-pulsed CRC organoids recorded during a live cell imaging experiment. [Figure 11I] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11I: Quantification of killing of IFN-γ-treated CRC organoids by specific T cells either in the presence or absence of a blocking antibody against PD-1. Graphs are representative of multiple replicate experiments using either EBV peptide and EBV T cells or WT1 peptide and WT1 T cells co-cultures. [Figure 11J] CRC organoids as a tool to assess antigen-specific killing by CD8+ T cells. Figure 11J: Quantification of cell viability after 18 hours of co-culture of either peptide-pulsed or non-pulsed HLA-A2+ organoids with antigen-specific T cells. Graph represents the ratio between peptide-pulsed and non-peptide-pulsed conditions. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] Detailed Description of the Invention definition "Allogeneic" refers to entities (e.g., cells, tumoroids, co-cultures) derived from different patients. In the case of cells, this can refer to cells derived from samples from different patients or healthy controls. Examples of suitable samples include, but are not limited to, peripheral blood or tissue biopsies.
[0028] "Approximately" or "about" as used in this application are equivalent. Any numbers used in this application, whether with or without about / approximately, are intended to cover any normal fluctuations understood by those of ordinary skill in the art. As used herein, the term "approximately" or "about" as applied to one or more values of interest refers to a value similar to the stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that is within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater or less) of the stated reference value, unless otherwise stated or clear from the context (except where such number would exceed 100% of possible values).
[0029] "Biologically active" refers to the characteristic of any agent that has activity in a biological system, particularly an organism. For example, an agent that, when administered to an organism, has a biological effect on the organism is considered to be biologically active.
[0030] "Co-culture" refers to two or more cell types that are maintained in suitable conditions for mutual growth.In the context of the present disclosure, "organoid co-culture" refers to epithelial organoids defined elsewhere in culture with non-epithelial cell types, particularly immune cell types.In some embodiments, the cell types in co-culture exhibit structural, biochemical, and / or phenomenological associations that they do not exhibit in isolation.In some embodiments, the cell types in co-culture mimic the structural, biochemical, and / or phenomenological associations observed between cell types in vivo.
[0031] "Comprise," "comprises," and "comprising" are understood to imply the inclusion of a stated step or element or group of steps or elements, but not the exclusion of any other steps or elements or groups of steps or elements.
[0032] "Dose" refers to a specific amount of pharmaceutical agent provided in a single administration. In certain embodiments, a dose may be administered in two or more boluses, tablets, or injections. For example, in certain embodiments, when subcutaneous administration is desired, the desired dose requires a volume that is not easily accommodated by a single injection. In such embodiments, two or more injections may be used to achieve the desired dose. In certain embodiments, a dose may be administered in two or more injections to minimize an individual's injection site reaction. In certain embodiments, a dose is administered as a slow infusion.
[0033] "Immune disease" refers to any disorder of the immune system. Immune diseases usually have a genetic component and include autoimmune diseases (in which the immune system misacts against "self" components) and immune-mediated diseases (in which the immune system is overactive).
[0034] "Immunotherapy" refers to any medical intervention that induces, suppresses or enhances the patient's immune system for the treatment of disease. In some embodiments, immunotherapy activates the patient's innate and / or adaptive immune response (e.g., T cells) to more effectively target and eliminate pathogens or cure diseases such as cancer or immune diseases.
[0035] "Intestine" and "intestinal" refer to the gastrointestinal tract, including the mouth, oral cavity, esophagus, stomach, large intestine, small intestine, rectum, and anus.
[0036] "Organoid" refers to a cellular structure obtained by the proliferation of adult (post-embryonic) epithelial stem cells, preferably characterized by Lgr5 expression, and composed of tissue-specific cell types that self-organize through cell sorting and spatially restricted lineage commitment (see, for example, Clevers, Cell. 2016 Jun 16;165(7):1586-1597, especially the section entitled "Organoids derived from adult stem cells" starting on page 1590). In this application, the term "organoid" may be used to refer to normal (e.g., non-tumor) organoids. When an organoid is described as a "disease" organoid, this means that the organoid has a disease phenotype, for example, because the organoid is derived from one or more epithelial stem cells that usually have a disease phenotype, or in some embodiments, the organoid has been genetically modified to display certain characteristics of the disease phenotype.
[0037] "Population" refers to a group of entities that share a common trait. In some embodiments, "population" refers to patients that share a set of related clinical traits. Preferably, "population" may refer to a group of patients that share the same cancer and / or are treated with the same agent and / or are susceptible to successful treatment with the same agent. Populations may differ in one or more characteristics, including genotype and / or response characteristics to a particular agent during treatment. Populations may also refer to a group of cells, organoids, and / or co-cultures that share one or more genotypes, phenotypes, or biochemical traits. "Subpopulation" refers to a group of entities that share a greater number of common traits or a smaller number of dissimilar traits than the larger population into which the subpopulation entities are also classified.
[0038] "Safe" refers to the treatment of a disease that has no side effects, or only side effects that are within tolerable levels according to standard clinical practice.
[0039] "Side effects" or "adverse effects" refer to physiological responses attributable to a treatment other than the desired effects.
[0040] "Subject" or "patient" or "individual" may refer to a human or any non-human animal, such as any mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate. In a preferred embodiment, the patient is a mammal, more preferably a human. "Human" may refer to prenatal and / or postnatal forms. A subject may be a patient, which refers to a human being presented to a health care provider for diagnosis or treatment of a disease. The term "subject" is used interchangeably herein with "individual" or "patient." A patient may be suffering from a disease or disorder or may be susceptible to a disease or disorder, but may or may not show symptoms of the disease or disorder.
[0041] "Suffering from" refers to a patient who has been diagnosed with or who exhibits one or more symptoms of a disease, disorder, and / or condition.
[0042] "Susceptible" refers to a patient who has not been diagnosed with a disease, disorder, and / or condition. In some embodiments, a patient who is susceptible to a disease, disorder, and / or condition may not exhibit symptoms of the disease, disorder, and / or condition. In some embodiments, a patient who is susceptible to a disease, disorder, condition, or event may be characterized by one or more of the following: (1) a genetic mutation associated with the onset of the disease, disorder, and / or condition; (2) a genetic polymorphism associated with the onset of the disease, disorder, and / or condition; (3) an increased and / or decreased expression and / or activity of a protein associated with the disease, disorder, and / or condition; (4) a habit and / or lifestyle associated with the onset of the disease, disorder, condition, and / or (5) having undergone, intending to undergo, or needing a transplant. In some embodiments, a patient who is susceptible to a disease, disorder, and / or condition develops the disease, disorder, and / or condition. In some embodiments, a patient who is susceptible to a disease, disorder, and / or condition does not develop the disease, disorder, and / or condition.
[0043] A "therapeutically effective amount" refers to an amount of a therapeutic agent sufficient to treat, diagnose, prevent, and / or delay the onset of symptoms of a disease, disorder, and / or condition when administered to a subject suffering from or susceptible to a disease, disorder, and / or condition. It will be understood by those skilled in the art that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
[0044] "Treating," "treat," and "treatment" refer to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a particular disease, disorder, and / or condition. Treatment may be administered to subjects who do not exhibit signs of the disease and / or who exhibit only early signs of the disease, with the intent of reducing the risk of developing pathology associated with the disease.
[0045] "Tumoroid" refers to organoids that contain cells that exhibit one or more genetic, phenotypic, or biochemical traits that are classified as cancerous.In this application, the term "tumoroid" includes "organoids" derived from cancerous tissue.The term "tumoroid" may also include tumor progression organoids (TPOs), which are engineered tumor organoid cultures, for example, normal organoids are engineered to contain cancer mutations using Cas9 technology.
[0046] Identification of therapeutically relevant agents General. The present invention relates to co-cultures of organoids and immune cells ("organoid co-cultures") and / or co-cultures of diseased organoids (such as tumoroids) and immune cells ("diseased organoid co-cultures" or more specifically "tumoroid co-cultures"), and their use to investigate the physiology of disease and / or the suitability of candidate agents for treating disease. Suitability for treating disease may include efficacy for treating disease and / or safety for treating disease. Diseases of particular interest include cancer and immune diseases.
[0047] Thus, the present invention provides, inter alia, a method for identifying an agent suitable for treating cancer, the method comprising: contacting the tumouroid co-culture with one or more candidate agents, wherein the tumouroid co-culture comprises immune cells and at least one tumouroid; detecting the presence or absence of one or more alterations in the tumoroid co-cultures that indicate the suitability of the candidate agent for the treatment of cancer; and Identifying the candidate agent as suitable for treating cancer when the presence or absence of one or more of said alterations is detected in the tumoroid co-cultures.
[0048] Also provided is a method of testing a therapeutic agent, the method comprising: contacting the organoid co-culture with one or more candidate agents, wherein the organoid co-culture comprises immune cells and at least one organoid; Detecting the presence or absence of one or more changes in the organoid co-culture that are indicative of therapeutic efficacy; and If the presence or absence of one or more of said changes is detected in the organoid co-culture, the candidate agent is identified as a therapeutic agent.
[0049] In some embodiments, organoid is disease organoid, for example, the organoid shows immune disease phenotype.Because immune cells exist in the co-culture of the present invention, the co-culture is particularly suitable for investigating the suitability of candidate immunotherapeutic agents.
[0050] The methods of the present invention have high throughput (HTP) capabilities. In some embodiments, the methods of the present invention can be carried out on 96-well plates and / or 384-well plates.
[0051] Contacting step. This may involve exposing the organoid co-culture to a therapeutic level of a known or unknown therapeutic agent. Typically, the agent is dissolved in a solution to a (predicted) therapeutically effective concentration and administered to the co-culture by injection (or other suitable administration) into the vessel in which the co-culture is maintained.
[0052] Detection Step In some embodiments, the present invention comprises detecting the presence or absence of one or more changes in the tumoroid co-cultures that indicate the suitability of a candidate agent for treatment.
[0053] In principle, any biochemical, genetic, phenotypic or phenomenological change in co-culture may be detected.In some embodiments, one or more changes may be in one or more disease biomarkers, such as cancer biomarkers.In some embodiments, one or more changes may include reduced cell viability, reduced cell proliferation, increased cell death, changes in cell or organoid size, changes in cell motility, dissociation or destruction of intact / compact epithelial cell layer (i.e., cells dissociate from compact epithelial cell layer), changes in the production of cytokines and cytotoxic molecules by co-cultured immune cells, and changes in the expression of one or more genes.
[0054] In principle, detection may be carried out using any suitable laboratory method known to those skilled in the art. In some embodiments, detection of one or more changes may include cell proliferation assays, viability assays, flow cytometry analysis, ELISA for IFN-γ (interferon gamma) (e.g., as performed in FIG. 8D), analysis of gene expression, and / or cell imaging.
[0055] Reduction in cell viability may be detected by CellTiter Glo Luminescent Cell Viability Assay kit (Promega), intracellular flow cytometry staining for active caspase 3 (BD), or positive staining for dead cells. Positive strains of dead cells include non-cell membrane permeable DNA stains such as NucRed Dead 647 ReadyProb.
[0056] Increased cell death may be detected by bright field imaging.
[0057] Identification Step. Identification may involve identifying a particular magnitude of change and may be an automated and / or high throughput process.
[0058] Comparison step. In some embodiments, the present invention can include the step of comparing organoid co-culture or tumouroid co-culture with a control, which may or may not be associated with identification step. This can involve the comparison of the presence or absence or size of one or more changes of tumouroid co-culture with reference organoid or reference tumouroid, and can further include: contacting a reference organoid or a reference tumoroid co-culture with one or more candidate agents, wherein the reference organoid or the reference tumoroid co-culture comprises immune cells and at least one organoid; and Detecting the presence or absence of one or more changes in the reference organoid or reference tumoroid co-culture that indicate the suitability of the candidate agent for the treatment of cancer.
[0059] In some embodiments, a candidate agent is identified as a suitable agent if the presence or absence of an alteration is detected in the tumoroid co-culture but not in the reference co-culture.
[0060] In some embodiments, a reference organoid co-culture or a reference tumoroid co-culture is used as a control, such as a negative control or a positive control.
[0061] Selection step. In some embodiments, the method of the present invention comprises selecting a candidate agent suitable for treating cancer. Selection can involve the consideration of the presence or absence or magnitude of one or more changes of the method provided, so selection is distinct from identification. For example, selection can include additional considerations such as the bioavailability of the agent, applicability to a subpopulation of patients, or the delivery mechanism of the agent, which may or may not be tested in the method.
[0062] In some embodiments, this step may be the final step of the method of the invention. In other embodiments, further steps are envisioned. For example, the method of the invention may further include using the selected candidate agent in a therapy.
[0063] Agents. Any agent may be tested by the methods of the invention, including any biological, chemical, physical, or other agent, or multiple agents administered simultaneously or sequentially.
[0064] Agents (or "candidate agents") being tested for suitability for cancer treatment may be selected from one or more of the following therapeutic classes: immunotherapeutics, tumor-specific peptides, checkpoint inhibitors, alkylating agents, antimetabolites, metabolic agonists, metabolic antagonists, plant alkaloids, mitotic inhibitors, antitumor antibiotics, topoisomerase inhibitors, radiotherapeutics, chemotherapeutics, antibodies, photosensitizers, transplanted stem cells, vaccines, cytotoxic agents, cytostatic agents, tyrosine kinase inhibitors, proteasome inhibitors, cytokines, interferons, interleukins, intercalating agents, targeted therapy agents, small molecule drugs, hormones, steroids, cellular therapeutic agents, viral vectors, and nucleic acid therapeutic agents.
[0065] Preferably, the agent is a tumor-specific peptide, a checkpoint inhibitor, or an immunotherapeutic agent.
[0066] The agent is more preferably an immunotherapeutic agent, such as a chimeric antigen receptor (CAR)-T cell therapy, a therapeutic TCR transgenic T cell, or a neoantigen. Other agents include agents associated with antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP).
[0067] Context. The methods of the claimed invention may be performed in vivo, ex vivo, in vitro, in situ, ex situ, or any combination thereof. Preferably, the methods are performed in vitro.
[0068] Personalized Medicine General. One means of testing different regimens can be described as a "personalized medicine" approach to testing. A personalized medicine approach can involve testing one or more candidate agents with known suitability for treatment and / or identifying one or more candidate agents as suitable agents in a particular patient.
[0069] The application of the personalized medicine of the present invention may require that both the tumoroid co-culture and the reference organoid or reference tumoroid co-culture are derived from a particular patient for whom the suitability of a candidate agent for treating cancer has been identified.
[0070] The present inventors have demonstrated that immune cells, normal (e.g., non-tumor) epithelial cells, and tumor epithelial cells can be derived from a single tissue of a single patient, and that these cells can be used to obtain organoid-immune cell co-cultures and tumoroid-immune cell co-cultures. These co-cultures provide a particularly useful model for testing the response of individual patients to candidate agents.
[0071] Patients for whom a candidate agent has been identified as suitable for the treatment of cancer may subsequently be treated with the candidate agent so identified.
[0072] screening General. Another means of testing different regimens can be described as a "screening" approach to testing. A screening approach can involve testing one or more candidate agents with unknown suitability for treatment and / or identifying a subset of one or more candidate agents as suitable agents for treatment.
[0073] Applications of the screening methods of the present invention may require that one or more candidate agents have known suitability for treating a first cancer and unknown suitability for treating a second cancer, and that the screen involves identifying a subset of the one or more candidate agents as suitable agents for treating the second cancer.
[0074] In some embodiments, the screening approach identifies agents suitable for treating cancer at a "population" level, rather than at the level of a subpopulation. In other embodiments, the screening approach identifies agents suitable for treating cancer at the level of a subpopulation. In some embodiments, the screening approach is not used to identify agents suitable for treating cancer at the level of an individual patient (which is typically encompassed by a personalized medicine approach).
[0075] Cell types and diseases Species. The cell, cancer, organoid, and / or co-culture of the present invention or suitable for use in the method of the present invention can be any multicellular organism, preferably a multicellular organism susceptible to cancer.In some embodiments, the cell, cancer, organoid, and / or co-culture of the present invention is mammalian (meaning derived from mammalian), such as mouse, primate, or human cell, cancer, organoid, and / or co-culture.In a preferred embodiment, the cell, cancer, organoid, and / or co-culture of the present invention is human (meaning derived from human).
[0076] Epithelial cells. The organoid and / or organoid co-culture of the present invention is obtained from epithelial cells. The organoid and / or organoid co-culture may be obtained from normal (i.e., non-disease) epithelial cells or disease epithelial cells (sometimes specifically referred to as "disease organoid" or "disease co-culture"). The tumouroid and / or tumouroid co-culture of the present invention is obtained from tumor epithelial cells. Any epithelial cell that can produce organoid or tumouroid is suitable for use in the present invention. Preferred tumor epithelial cells and / or normal epithelial cells include lung cells, liver cells, breast cells, skin cells, intestinal cells, crypt cells, rectal cells, pancreatic cells, endocrine cells, exocrine cells, ductal cells, kidney cells, adrenal cells, thyroid cells, pituitary cells, parathyroid cells, prostate cells, stomach cells, esophageal cells, ovarian cells, fallopian tube cells, and vaginal cells. Particularly preferred epithelial cells are intestinal cells, such as colorectal cells. The epithelial cells may preferably be epithelial stem cells characterized by Lgr5 expression.
[0077] In some embodiments, tumor epithelial cells and / or normal epithelial cells are obtained from samples from cancer patients.In certain embodiments, tumor epithelial cells and normal epithelial cells are obtained from samples from the same cancer patient, optionally from the same sample.Suitable samples for obtaining epithelial cells include ascites from colorectal cancer or ovarian cancer patients; urine from renal cancer patients; or tissue biopsy, such as tissue biopsy from resected colon and / or rectum of colorectal cancer patients.
[0078] Immune cells. Any immune cells that can be incorporated into co-culture are suitable for use in the methods of the present invention. Preferred immune cells include one or more cell types selected from the group consisting of intraepithelial lymphocytes (IEL), tumor infiltrating lymphocytes (TIL), peripheral blood mononuclear cells (PBMC), peripheral blood lymphocytes (PBL), T cells, cytotoxic T lymphocytes (CTL), B cells, NK cells, mononuclear phagocytes, α / β receptor T cells, and γ / δ receptor T cells. Preferred immune cells also include myeloid-derived suppressor cells.
[0079] Immune cells may be obtained from established cell lines available in the art (e.g., from ATCC or similar libraries of cell lines). Alternatively, immune cells may be purified from impure samples from subjects. Obtaining immune cells from the same patient as the tumor epithelial cells for deriving tumoroids in co-culture has an associated advantage, since the resulting co-culture is thus the most representative (and therefore the most faithful model) of the patient from which the cells are derived. This is particularly useful in the context of personalized medicine.
[0080] Impure immune samples from which immune cells may be obtained may include tumor samples, normal (non-tumor) colon tissue, and / or peripheral blood. In some embodiments, immune cells are obtained from samples from cancer patients. In some embodiments, immune cells are obtained from peripheral blood samples and / or tissue biopsies. For example, peripheral blood lymphocytes (PBL) and / or T cells may be obtained from peripheral blood samples; or tumor-infiltrating lymphocytes (TIL) and / or intraepithelial lymphocytes (IEL) are obtained from tumor or healthy tissue biopsies, respectively.
[0081] The immune cells suitable for use in the method of the present invention can be allogeneic with tumouroid and / or organoid.In some embodiments, the immune cells can be HLA-matched with tumouroid and / or organoid, i.e., the immune cells can be antigenically matched with the patient from whom tumouroid and / or organoid is derived (Shiina et al., (2016). MHC Genotyping in Human and Nonhuman Species by PCRbased Next-Generation Sequencing, Next Generation Sequencing - Advances, Applications and Challenges, Dr. Jerzy Kulski (Ed.), InTech, DOI: 10.5772 / 61842) (Choo, Yonsei Med J. 2007 Feb 28;48(1):11-23).
[0082] T cell engineering. An important aspect of the present invention is the use of engineered T cells, such as chimeric antigen receptor (CAR)-T cells (Sadelain et al., Nature. 2017 May 24;545(7655):423-431). The present invention provides methods and co-cultures that can be used to test the suitability of different CAR-T cell types for different tumor phenotypes and tumor microenvironments. The present invention is an advantageous means of streamlining the process of CAR-T cell selection and performance expansion, with improved scalability and reduced costs compared to existing methods. In particular, the present invention is highly suitable for use with γδ T cells - non-conventional T cells with potent anti-tumor reactivity against a wide range of tumors with diverse tissue origins (Sebestyen et al., Cell Rep. 2016 May 31;15(9):1973-85). Thus, in some embodiments, the immune cells in the co-culture are engineered T cells, such as CAR-T cells.
[0083] Organoids and tumouroids. Organoids may be prepared by culturing normal epithelial cells in organoid culture medium. Tumoroids may be prepared by culturing tumor epithelial cells in tumouroid culture medium. Normal epithelial cells may be autologous to tumor epithelial cells (i.e., from the same patient). Organoids / tumouroids of the present invention may be characterized by Lgr5 expression. In some embodiments, organoids / tumouroids are three-dimensional cell structures. In some embodiments, organoids / tumouroids comprise a lumen surrounded by epithelial cells. In some embodiments, the epithelial cells surrounding the lumen are polarized. In tumouroids, polarization may be destroyed. The epithelial cells from which organoids / tumouroids are obtained are preferably primary epithelial cells.
[0084] Cancer Types The methods of the present invention are applicable to any cancer. In some embodiments, the cancer may be one or more of adenoma, adenomatous polyp, renal carcinoma, adrenal adenoma, thyroid adenoma, pituitary adenoma, parathyroid adenoma, hepatocellular adenoma, fibroadenoma, cystadenoma, bronchial adenoma, sebaceous adenoma, prostatic adenoma, adenocarcinoma, cholangiocarcinoma, squamous cell carcinoma, ductal carcinoma, lobular carcinoma, carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, large cell carcinoma, small cell carcinoma, spindle cell carcinoma, sarcomatoid carcinoma, pleomorphic carcinoma, carcinosarcoma, basal cell carcinoma, VIPoma, linitis plastica, adenoid cystic carcinoma, renal cell carcinoma, mucoepidermoid carcinoma, large intestine cancer, small intestine cancer, colon cancer, colorectal cancer, gastrointestinal cancer, esophageal cancer, rectal cancer, vaginal cancer, pancreatic cancer, gastric cancer, ovarian cancer, cervical cancer, endometrial cancer, small cell lung cancer, non-small lung cancer, breast cancer, and melanoma.
[0085] Cancers to which the methods of the invention are particularly applicable include epithelial cancers such as gastrointestinal or colorectal cancer, pancreatic cancer, and breast cancer.
[0086] Stages of Cancer. The present invention is applicable to cancer at any stage of progression. Cancer progression may be characterized in several different systems. The TNM (Tumor, Node, Metastasis) system is made up of three categories, each assigned a numerical degree. T refers to the size of the cancer and how far it has spread to nearby tissues - this can be 1, 2, 3, or 4, with 1 being small and 4 being large. N refers to whether the cancer has spread to lymph nodes - this can be between 0 (no lymph nodes containing cancer cells) and 3 (many lymph nodes containing cancer cells). M refers to whether the cancer has spread to another part of the body - this can be either 0 (cancer has not spread) or 1 (cancer has spread). The second system is the Numerical Staging System, which is made up of four stages. Stage 1 typically means that the cancer is relatively small and contained within the organ where it started. Stage 2 typically means that the cancer has not started to spread to the surrounding tissues, but the tumor is larger than stage 1. Sometimes, stage 2 means that cancer cells have spread to lymph nodes near the tumor. This depends on the particular cancer type. Stage 3 usually means the cancer is larger. It may have started to spread to surrounding tissues and there are cancer cells in lymph nodes in the area. Stage 4 means the cancer has spread from where it started to another organ in the body. This is also called secondary or metastatic cancer. The Grading System is a third system that characterizes the extent of cancer progression. In Grade I, cancer cells resemble normal cells and are not growing rapidly. In Grade II, cancer cells do not look like normal cells and grow faster than normal cells. In Grade III, cancer cells look abnormal and may grow or spread more aggressively.
[0087] In the absence of metastasis, surgical resection is often sufficient, and therefore certain agents tested in the methods of the invention, such as immunotherapy, are more appropriate for later (metastatic) stages of cancer, such as colorectal cancer. Thus, the invention is applicable to cancers at or below stage III, grade III, or T2 N1 M1.
[0088] For other cancers that are not easy to surgically remove, immunotherapy may also be appropriate at earlier stages.In addition, the use of the present invention on tumor progression organoid (TPO) also allows the investigation of the treatment of cancer at earlier stages.Therefore, the present invention is applicable to one or below stage II, grade II, or T2 N1 M0 cancer.
[0089] Immune diseases. In addition to cancer, diseases of immune cells may also be investigated using the method of the present invention. In principle, any disorder of the immune system that affects immune cells may be investigated in co-culture. Preferred immune diseases include immune diseases of the digestive and respiratory systems, especially the intestine and lungs. Exemplary immune diseases include irritable bowel disease (IBD), ulcerative colitis (UC), chronic obstructive pulmonary disease (COPD), and asthma.
[0090] When using the methods of the invention to test for immune disorders, organoids may be cultured separately with diseased immune cells and immune cells from healthy control patients.
[0091] Biopsy and sample procurement. Organoid and / or tumoroid samples can be obtained from normal mucosa and tumor tissue during surgery, for example, from the resected colon, rectum, small intestine, and / or ileum of colorectal cancer patients and / or healthy control patients. Immune cells can be derived from peripheral blood collected during surgery.
[0092] Organoids, tumoroids, and co-cultures Preparation of tumouroid co-culture. In one aspect, the present invention provides a method for preparing tumouroid-immune cell co-culture. The method comprises mixing the tumouroid described herein with immune cells in in vitro culture. Mixing can comprise sequentially layering T cells and organoids in the same well in a multi-well plate, or sequentially pipetting T cells and organoids into gel. In a preferred embodiment, tumouroid co-culture is maintained in co-culture medium described herein.
[0093] In some embodiments, the method for preparing a tumorigenesis-immune cell co-culture further comprises one or more of the following preparation steps: Preparing at least one tumoroid by culturing tumor epithelial cells in tumoroid culture medium; and / or Preparing immune cells by culturing the immune cells in an immune cell growth medium.
[0094] In a preferred embodiment, the at least one tumoroid culture medium (optionally including any extracellular matrix) is removed from the at least one tumoroid before mixing the at least one tumoroid with immune cells. Commercially available kits such as Cell Recovery Solution™ (Corning) can be used to destroy the extracellular matrix. Alternative matrices such as collagen can be used to replace the removed matrix.
[0095] In some embodiments, the method further comprises obtaining immune cells from impure immune samples.The method of isolating immune cells from impure immune samples is known in the art.The exemplary method of isolating lymphocytes from single cell suspension and T cell expansion culture is described in Example 5.
[0096] The present invention provides a tumorigenesis-immune cell co-culture obtained by the above method. The present invention also provides the use of the tumorigenesis-immune cell co-culture in drug screening, toxicity screening, academic research, and drug development.
[0097] Tumoroid co-cultures can be ex situ, ex vivo, and / or in vitro, preferably in vitro.
[0098] Preparation of organoid co-culture.In one aspect, the present invention provides a method for preparing organoid-immune cell co-culture.This method comprises mixing the organoid described herein with immune cell in in vitro culture.In a preferred embodiment, organoid co-culture is maintained in the co-culture medium described herein.
[0099] In some embodiments, the method for preparing an organoid-immune cell co-culture comprises one or more of the following steps: Preparing at least one organoid by culturing normal epithelial cells in an organoid culture medium; and / or Culturing immune cells in immune cell growth medium.
[0100] In a preferred embodiment, before mixing at least one organoid with immune cells, the organoid culture medium (optionally including any extracellular matrix such as basement membrane matrix "BME" or Matrigel) is removed from at least one organoid.Extracellular matrix can be destroyed using commercially available kits such as Cell Recovery Solution™ (Corning).Replace removed matrix with alternative matrix such as collagen.
[0101] In some embodiments, the method further comprises obtaining immune cells from impure immune samples.The method of isolating immune cells from impure immune samples is known in the art.The exemplary method of isolating lymphocytes from single cell suspension and T cell expansion culture is described in Example 5.
[0102] The present invention also provides the organoid-immune cell co-culture obtained by the above method.The present invention also provides the use of the organoid-immune cell co-culture in drug screening, toxicity screening, academic research and drug development.
[0103] Organoid co-cultures can be ex situ, ex vivo, and / or in vitro, preferably in vitro.
[0104] Primary analysis. In some embodiments, the method of the present invention further comprises one or more steps of primary analysis. Primary analysis of tumouroids and / or organoids may include whole genome sequencing, mRNA sequencing, peptidome profiling, and / or microscopy. Primary analysis can be used to ensure that tumouroids and / or organoids are homogeneous and / or meet expectations, as a form of information disclosure and / or information verification. For example, primary analysis can be used to determine the differences in mRNA transcription between organoids and tumouroids, and whether these differences in mRNA transcription are reflected in differences in protein expression. The presence of specific antigens on organoids / tumouroids, and whether any new antigens occur only on tumouroids, may also be confirmed. The upregulation of immune suppressive factors in the tumor microenvironment by tumor cells may also be investigated.
[0105] Immune cells may be subjected to one or more steps of primary analysis. For example, primary analysis of immune cells may include immunophenotyping and / or T cell receptor sequencing. Primary analysis can be used to confirm that CAR-T cells express the receptors required for tumor cell recognition. The upregulation of specific receptors that recognize tumors may also be investigated.
[0106] In certain embodiments, the methods of the present invention include determining the HLA type of the cells, organoids, or tumoroids.
[0107] Co-culture may be subjected to one or more steps of primary analysis. Primary analysis of tumoroid co-culture and / or organoid co-culture may include imaging analysis, flow cytometry analysis, and / or cytokine secretion analysis. Primary analysis can be used to ensure that co-culture is uniform and / or meets expectations.
[0108] Source of tumoroids and organoids.Tumoroids and / or organoids of the present invention may comprise or consist of autologous cells, i.e. cells obtained from the same patient.For example, tumoroids may be obtained by culturing tumor cells (e.g., colorectal cancer cells), while organoids may be obtained by culturing normal (non-tumor) cells (e.g., normal colon cells) from the same tissue in the same patient.This may be particularly useful in terms of reference organoids.
[0109] The present invention also provides tumoroid and / or organoid in medium that contains interleukin such as IL-2, IL-7 or IL-15.In some embodiments, at least one tumoroid or at least one organoid comprises or consists of mammalian cell, preferably human cell.
[0110] Separation of tumouroids and organoids.In some embodiments, tumouroids and / or organoids are separated into groups that share one or more genotypes, phenotypes and / or epigenetic markers before mixing with immune cells.Preferably, genotypes, phenotypes and / or epigenetic markers contribute to the interaction between (i) tumouroids and / or organoids and (ii) immune cells.
[0111] Populations isolated from tumoroids or organoids may share the presence or absence of an HLA haplotype, for example an HLA haplotype such as HLA-A2.
[0112] This separation step may allow relevant patient groups and subgroups to be determined.
[0113] Culture medium Immune cell culture medium. Immune cell culture medium may be used to prepare immune cells for co-culture, for example, by promoting the growth and division (proliferation) and / or differentiation of immune cells to produce a population suitable for co-culture.
[0114] In a preferred embodiment, the immune cell culture medium comprises an interleukin. In some embodiments, the interleukin is selected from IL-2, IL-7, and IL-15. In a preferred embodiment, the interleukin in the immune cell culture medium is IL-2.
[0115] In some embodiments, the concentration of interleukin is 2000-6000 IU / mL. The preferred concentration of IL-2 in the immune cell culture medium is 50 μM.
[0116] The immune cell culture medium may further comprise RPMI medium (e.g., RPMI 1640, Gibco) optionally supplemented with penicillin / streptomycin and / or hepes and / or glutaMAX™ and / or sodium pyruvate and / or serum (e.g., 5% human AB serum, Sigma-Aldrich). In principle, any mammalian cell culture basal medium may be used instead of RPMI medium, such as DMEM / 12.
[0117] Organoid and Tumoroid Culture Media. Tumoroid culture media and organoid culture media may be used to prepare organoids and tumouroids for co-culture, for example by promoting growth, division (proliferation), structural organization, or other development to produce tumouroids and / or organoids suitable for co-culture.
[0118] Suitable tumoroid and organoid culture media for different tissues are known in the art (e.g., Clevers, Cell. 2016 Jun 16;165(7):1586-1597). A preferred organoid / tumoroid culture medium comprises a Wnt agonist (e.g., any one of R-spondin 1-4), a mitogenic growth factor (e.g., selected from EGF, FGF, HGF, and BDNF), and a BMP inhibitor (e.g., noggin) (e.g., as described in WO2010 / 090513). In some embodiments, the organoid / tumoroid culture medium further comprises a TGF-beta inhibitor (e.g., A83-01, Tocris) (e.g., as described in WO2012 / 168930). The addition of a TGF-beta inhibitor is particularly suitable for culturing human cells. The TGF-beta inhibitor preferably inhibits the ALK4 / 5 / 7 signaling pathway.
[0119] In some embodiments, certain culture medium components are optional for tumoroid culture medium because certain tumor cells contain mutations that constitutively activate or inactivate pathways (such as the Wnt pathway), thus eliminating the need for exogenous factors designed to regulate these pathways. Thus, for example, in some embodiments, tumoroid culture medium does not contain Wnt agonists.
[0120] A preferred organoid culture medium, particularly suitable for culturing colonic organoids, comprises a basal medium (such as Advanced DMEM / F12 medium, Gibco), one or more (or preferably all) of a Wnt ligand (such as Wnt-3a), a Wnt agonist (such as any one of Rspondin 1-4), a BMP inhibitor (such as Noggin), EGF, and a TGF-β inhibitor (such as A83-01, Tocris), and optionally further comprises one or more (or all) of a p38 MAPK inhibitor, gastrin, nicotinamide, prostaglandin E, N-acetylcysteine, B27, and / or an antimicrobial agent (such as Primocin).
[0121] A preferred tumoroid culture medium, particularly suitable for culturing colon cancer tumoroids, comprises a basal medium (such as Advanced DMEM / F12 medium, Gibco), one or more (or preferably all) of a Wnt agonist (such as any one of Rspondin 1-4), a BMP inhibitor (such as Noggin), EGF, and a TGF-β inhibitor (such as A83-01, Tocris), and optionally further comprises one or more (or all) of a p38 MAPK inhibitor, gastrin, nicotinamide, prostaglandin E, N-acetylcysteine, B27, and / or an antimicrobial agent (such as Primocin). The tumoroid culture medium may optionally contain a Wnt ligand (such as Wnt-3a), which is particularly useful for colorectal tumors that are most sensitive to immunotherapy (e.g., MSI tumors that normally lack mutations in the Wnt pathway).
[0122] In some embodiments, the tumoroids or organoids are cultured in immune cell growth medium or a mixture of immune cell growth medium and a preferred tumoroid or organoid culture medium.
[0123] Those skilled in the art will know culture media specific to other types of organoids and tumoroids and can adapt the present invention accordingly for use with other organoids and tumoroids.
[0124] Co-culture medium. The present invention provides a medium (for example, as described in the examples) for co-culture of tumouroid and immune cells. The present invention also provides a medium (for example, as described in the examples) for co-culture of organoid and immune cells. Any of the above immune cell culture medium or tumouroid / organoid culture medium can be used as the co-culture medium for culturing immune cell-organoid / tumouroid co-culture.
[0125] The co-culture medium of the present invention advantageously allows the co-culture of immune cells and organoids / tumoroids. In the case of tumoroids, such co-culture is difficult or even impossible without the use of the medium adaptations adopted in the co-culture medium of the present invention. The inventors have observed for the first time that the medium for co-culture between tumoroids and immune cells benefits from reduced Wnt components (compared to organoid culture medium) to protect immune cell function. This can be achieved by performing the co-culture in 100% immune cell culture medium or in a mixture between immune cell culture medium and organoid / tumoroid culture medium. For organoid co-culture, the reduced Wnt components are less beneficial, but the same medium can be used for the co-culture of organoids and immune cells.
[0126] Thus, in some embodiments, the co-culture medium comprises partly immune cell culture medium (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%) and partly organoid / tumoroid cell culture medium (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%). For example, in a preferred embodiment, the co-culture medium comprises about 50% immune cell culture medium and about 50% tumoroid / organoid culture medium. In some embodiments, the tumoroid culture medium is depleted of Wnt components before use in the mixture between immune cell culture medium and organoid / tumoroid culture medium.
[0127] In some embodiments, immune cell culture medium (such as T cell medium, e.g., RPMI 1640 (Gibco)) is used for the co-culture medium. This culture medium is particularly useful for supporting the maintenance of immune cells, particularly human immune cells, in co-culture. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the co-culture medium consists of immune cell culture medium.
[0128] Extracellular matrix. Cells are preferably cultured in a microenvironment that at least partially mimics the cell niche in which the cells naturally reside. The cell niche is determined in part by the cell and by the extracellular matrix (ECM) secreted by the cells within the niche. The cell niche may be mimicked by culturing the cells in the presence of a biomaterial or synthetic material that provides for interaction with cell membrane proteins, such as integrins. Thus, the extracellular matrix described herein is any biomaterial or synthetic material, or combination thereof, that mimics the in vivo cell niche, for example by interacting with cell membrane proteins, such as integrins. Any suitable extracellular matrix may be used.
[0129] In the preferred method of the present invention, cells are cultured in contact with ECM."In contact" means physical or mechanical or chemical contact, which means that force must be used to separate the resulting organoid or epithelial cell population from extracellular matrix.In some embodiments, ECM is a three-dimensional matrix.In some embodiments, cells are embedded in ECM.In some embodiments, cells are attached to ECM.The culture medium of the present invention can diffuse into three-dimensional ECM.
[0130] In another embodiment, the ECM is in suspension, i.e., the cells are in contact with the ECM in a suspension system. In some embodiments, the ECM is in suspension at a concentration of at least 1%, at least 2%, or at least 3%. In some embodiments, the ECM is in suspension at a concentration of 1% to about 10% or 1% to about 5%. Suspension methods may have advantages for upscale methods.
[0131] One type of ECM is secreted by epithelial cells, endothelial cells, parietal endoderm-like cells (e.g., Englebreth Holm Swarm Parietal Endoderm Like cells, described in Hayashi et al. (2004) Matrix Biology 23:47 62), and connective tissue cells. This ECM is composed of various polysaccharides, water, elastin, and glycoproteins, where glycoproteins include collagen, entactin (nidogen), fibronectin, and laminin. Thus, in some embodiments, the ECM for use in the methods of the invention comprises one or more components selected from the list: polysaccharides, elastin, and glycoproteins, e.g., glycoproteins include collagen, entactin (nidogen), fibronectin, and / or laminin. For example, in some embodiments, collagen is used as the ECM. Different types of ECMs are known that include different compositions, including different types of glycoproteins and / or different combinations of glycoproteins.
[0132] Examples of commercially available extracellular matrices include: extracellular matrix proteins (Invitrogen) and basement membrane preparations from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells (e.g., Cultrex® Basement Membrane Extract (Trevigen, Inc.) or Matrigel™ (BD Biosciences)).
[0133] In some embodiments, the ECM is a laminin-containing ECM, such as Matrigel™ (BD Biosciences). In some embodiments, the ECM is Matrigel™ (BD Biosciences), which contains laminin, entactin, and collagen IV. In some embodiments, the ECM contains laminin, entactin, collagen IV, and heparin sulfate proteoglycan (e.g., Cultrex® Basement Membrane Extract Type 2 (Trevigen, Inc.)). In some embodiments, the ECM contains at least one glycoprotein, such as collagen and / or laminin. If desired, a mixture of naturally produced or synthetic ECM materials may be used. In some embodiments, the ECM is BME ("basement membrane extract"), which is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumors (e.g., Cultrex® BME).
[0134] In another embodiment, the ECM can be synthetic ECM. For example, synthetic ECM such as ProNectin (Sigma Z378666) can be used. In a further example, the ECM can be plastic, such as polyester, or hydrogel. In some embodiments, the synthetic matrix can be coated with biomaterial, such as one or more glycoproteins, such as collagen or laminin.
[0135] The 3D ECM supports the culture of 3D epithelial organoids. The extracellular matrix material is usually a drop on the bottom of the dish in which the cells are suspended. Once the matrix has solidified, usually at 37°C, medium is added and allowed to diffuse into the ECM. The cells in the medium attach to the ECM by interactions with its surface structures, for example with integrins.
[0136] The culture medium and / or cells may be disposed on, embedded in, or mixed with the ECM.
[0137] Preferred ECMs for culturing tumoroids / organoids include BME and Matrigel.
[0138] A preferred ECM for culturing the co-culture is collagen, such as rat tail collagen I. Rat tail collagen I has been shown to improve immune cell motility during co-culture - see Example 11. Collagen may constitute at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, or at least 10% (v / v) of the co-culture.
[0139] Interleukins. The co-culture medium may contain an interleukin (IL), optionally one or more of interleukin or IL-2 (at a concentration of 100-200 IU / mL), IL-7 (at a concentration of 10-100 ng / mL), and IL-15 (at a concentration of 10-100 ng / mL). The preferred interleukin concentration used in the co-culture medium is 25 μM. These concentrations for co-culture are in contrast to the higher IL concentrations used in proliferation (e.g., for immune cell proliferation IL-2 is used at a concentration of 2000-6000 IU / mL).
[0140] IL-2 is the preferred interleukin for use with tumor-associated immune cells. For other immune cells, or immune diseases such as irritable bowel syndrome (IBD) or ulcerative colitis (UC), IL-7 and / or IL-15 are preferred (Rabinowitz et al., Gastroenterology. 2013 Mar;144(3):601-612.e1).
[0141] In some embodiments, the tumoroid co-culture medium and / or organoid co-culture medium comprises a mixture of (a) immune cell growth medium and (b) tumoroid culture medium or organoid culture medium, optionally wherein the media are present in a 50:50 (v / v) ratio.
[0142] Motility and protein concentration. In some embodiments, the co-culture and / or co-culture medium advantageously imparts improved motility to immune cells. Such co-culture and / or co-culture medium may include an extracellular matrix (ECM), as described above. The extracellular matrix may be Matrigel or BME. In a preferred embodiment, the extracellular matrix is collagen or rat tail collagen I.
[0143] The inventors have shown that the greatest improvement in motility is observed using collagen, particularly rat tail collagen I. In particular, immune cells (e.g., T cells) in BME-based medium exhibit an average track length of 43.635 μm, while immune cells (e.g., T cells) in rat tail collagen I-based medium exhibit an average track length of 135.08 μm. This is a three-fold increase in motility. The co-culture medium may contain a protein concentration of at least 0.15 mg / (ml Matrigel®) to 0.95 mg / (ml Matrigel®) for medium containing 2% to 10% Matrigel®.
[0144] In some embodiments, at least 20%, at least 30%, at least 40%, or at least 50% of the immune cells in the co-culture are able to migrate a distance of at least 200 μM, at least 250 μM, at least 300 μM, at least 350 μM, or at least 400 μM in 80 hours as determined using the assays of FIG. 3 and Example 10.
[0145] Persistence and duration of activity. In some embodiments, the media of the present invention allows immune cells to persist in immune cell expansion media for at least 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, or 240 hours.
[0146] In some embodiments, the media of the present invention allows immune cells to remain active for at least 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, or 72 hours after co-culture formation (i.e., after the time point of mixing immune cells with organoid / tumoroid cells).
[0147] In some embodiments, the medium of the present invention allows tumouroid co-culture to last in tumouroid co-culture medium, or reference organoid co-culture or reference tumouroid co-culture to last in organoid co-culture medium for at least 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, or 240 hours.In some embodiments, co-culture can last for 10 days or more, or for the same number of days that co-culture can remain in culture without subculturing.
[0148] The activity of immune cells can be detected by cell morphology (eg, the absence of roundness and the presence of cell processes indicates that the cells remain active).
[0149] Disclaimer. In some embodiments, IL-2 is not used in any of the media of the claimed invention.
[0150] Additional Methods and Products of the Invention Kits. The invention provides kits comprising any of the organoids, tumoroids, or co-cultures of the invention.
[0151] In some embodiments, the kit comprises one or more of the following: a syringe, an alcohol swab, a cotton ball, a gauze pad, instructions for carrying out the methods of the invention. EXAMPLES
[0152] Working Example Other features, objects, and advantages of the present invention will be apparent in the following examples. However, it should be understood that the examples, while showing aspects of the present invention, are given only as illustrations and not as limitations. Various changes and modifications within the scope of the present invention will be apparent to those skilled in the art from the examples. Although the present invention is illustrated using tumoroids as disease organoids, it is expected that other disease organoids, particularly disease organoids related to immune diseases, can be used in the same manner. Therefore, when the present disclosure refers to "tumoroids", it is intended to be replaced with "disease organoids", such as "immune disease organoids".
[0153] The following media are used in the examples: Human colon organoid medium. Complete Advanced DMEM / F12 medium (Gibco™) supplemented with 50% WNT3A conditioned medium (in-house), 20% R-spondin-1 conditioned medium (in-house), 10% Noggin conditioned medium (in-house), 1× B27 supplement (Gibco™), 1.25 mM N-acetylcysteine (Sigma-Aldrich), 10 mM nicotinamide (Sigma-Aldrich), 50 ng / mL human epidermal growth factor (EGF; Peprotech), 10 nM gastrin (Sigma-Aldrich), 500 nM TGF-β inhibitor A-83-01 (Tocris), 3 μM p38 MAPK inhibitor SB202190 (Sigma-Aldrich), 10 nM prostaglandin E2 (Tocris), and 100 mg / mL primocin (InvivoGen).
[0154] Human colorectal carcinoma tumouroid medium. Complete Advanced DMEM / F12 medium supplemented with 20% R-spondin-1 conditioned medium, 10% Noggin conditioned medium, 1x B27 supplement without Vitamin A (Gibco™), 1.25 mM N-acetylcysteine, 10 mM nicotinamide, 50 ng / mL human EGF, 10 nM gastrin, 500 nM TGF-β inhibitor A-83-01, 3 μM p38 MAPK inhibitor SB202190, 10 nM prostaglandin E2, and 100 mg / mL primocin.
[0155] Human T cell medium. RPMI 1640 (Gibco™) supplemented with penicillin / streptomycin, 5% human AB serum (Sigma-Aldrich).
[0156] Ijssel medium. IMDM supplemented with penicillin / streptomycin, 1% human AB serum (Sigma-Aldrich), bovine serum albumin, insulin, oleic acid, linoleic acid, transferrin, and ethanolamine (all Sigma-Aldrich).
[0157] In the following examples, the production and characterization of organoid and tumoroid co-cultures are described throughout Examples 1-9. Application of these methods and the co-cultures themselves are described in Examples 10-15.
[0158] Example 1. Collection of normal colon and colorectal cancer biopsies from a hospital. This example illustrates the isolation of cell samples used to prepare organoid, tumoroid, and immune cell samples in subsequent examples.
[0159] Biopsies of normal colonic mucosa and tumor tissue are taken from the resected colon and / or rectum of colorectal cancer patients. Peripheral blood is also collected during surgery.
[0160] Specifically, biopsies from human colorectal cancer tissues and normal (adult) human colonic mucosal epithelium were collected in 50 mL standard tubes containing 10–15 mL of ice-cold Advanced DMEM / F12 medium made complete with penicillin / streptomycin (10,000 U / mL penicillin and 10 μM / mL streptomycin from 100× stock), HEPES (1 M from 100× stock), GlutaMAX (from 100× stock; all Gibco™), and the Rho kinase inhibitor Y-27632 (Sigma-Aldrich). Biopsies kept on ice can be processed immediately or stored at 4 °C for up to 24 h until the start of isolation.
[0161] This process is shown diagrammatically in FIG. 1A.
[0162] Example 2. Isolation of crypts from normal colon tissue and derivation of normal colon organoids; isolation of intraepithelial T cells from normal colon tissue for T cell culture. This example illustrates the processing of normal colon samples for the generation of organoid cultures and the isolation of immune cells from normal colon samples.
[0163] Normal colonic mucosa is treated with EDTA to liberate crypts for derivation of normal colonic organoids, which are then further digested to generate a single cell suspension containing intraepithelial lymphocytes (IELs) for T cell culture.
[0164] Isolation of crypts from normal colon tissue and derivation of normal colon organoids. Remove the muscle layer and fat under a dissection microscope using surgical scissors and forceps. Cut the cleaned tissue into thin strips of roughly 1-2 mm. Fix one strip in 4% formaldehyde (Sigma-Aldrich) for histological analysis and flash freeze (in dry ice or liquid nitrogen) and store at -80 °C for gene and / or protein analysis. Dissolve the remaining strips in fresh chelating solution (5.6 mM Na dissolved in sterile water). 2 HPO 4 , 8.0 mM KH 2 PO4 , 96.2 mM NaCl, 1.6 mM KCl, 43.4 mM sucrose, and 54.9 mM D-sorbitol; all Sigma-Aldrich). The washed strips were incubated for 30 min at 4 °C on a rotating wheel (cold room) in chelating solution completed with 2 mM ethylenediaminetetraacetic acid (EDTA; in-house) and 0.5 mM DL-dithiothreitol (DTT; Sigma-Aldrich). The tubes were vigorously shaken to liberate the colonic crypts from the mesenchyme. If crypts were not visible, the incubation was repeated with fresh complete chelating solution. The tissue fragments were allowed to settle for 1–2 min, and the supernatant containing the crypts was transferred to a new tube. Five to ten mL of fetal calf serum (FCS; Sigma-Aldrich) was added, and the crypts were centrifuged at 300 × g for 5 min at 4 °C. The remaining tissue fragments were kept on ice for isolation of intraepithelial T cells. Crypts were washed three times with complete Advanced DMEM / F12. Crypts were resuspended in basement membrane extract (BME; Cultrex®), plated at different densities, and incubated at 37°C and 5% CO 2 The plates were then placed in a humidified incubator at 37 °C for 30 min. Upon solidification of the BME, human colon organoid medium supplemented with the Rho kinase inhibitor Y-27632 was added and replaced every 3–4 days. Organoids formed from the crypts were passaged every 7–10 days.
[0165] Primary analysis of the organoid cultures was subsequently performed using whole genome sequencing, mRNA sequencing, and peptidome profiling.
[0166] Isolation of intraepithelial T cells from normal colon tissue for T cell culture. The tissue fragments retained from the isolation of colonic crypts were placed in a Petri dish and cut into very small pieces (<1 mm) using forceps, scissors, and a scalpel. The tissue fragments were transferred to a 50 mL standard tube and washed three times with 20 mL of RPMI 1640 medium (Gibco™) completed with 10% FCS and penicillin / streptomycin to remove any remaining EDTA and inhibitors. After the tissue fragments had settled to the bottom of the beaker, the medium was removed with a pipette. The tissue fragments were then incubated with shaking in 10 mL of RPMI 1640 medium containing 1 mg / mL collagenase 1A, 10 U / mL DNase I (all Sigma-Aldrich), and the Rho kinase inhibitor Y-27632 for 1 h at 37°C. 2 mL of FCS was added to the cell suspension, and the entire suspension was filtered through a 100-μm cell strainer. The single cell suspension was centrifuged at 300×g for 5 min at 4° C. The supernatant was removed and the cell pellet was washed twice with complete RPMI 1640 medium. The single cell suspension was either cryopreserved in liquid nitrogen in freezing medium (either Recovery™ Cell Culture Freezing Medium or 10% DMSO in a 1:1 mixture of FCS and Advanced DMEM / F12, all Gibco™) or further processed for T cell culture.
[0167] Example 3. Digestion of colorectal cancer tissue for tumor organoids and T cell cultures; derivation of colorectal cancer tumoroids. This example demonstrates the processing of cancerous colon samples for the generation of tumorigenesis cultures and the isolation of immune cells from cancerous colon samples. Tumor tissue is digested to produce a single cell suspension containing epithelial tumor cells for the derivation of tumorigenesis and tumor infiltrating lymphocytes (TILs) for T cell cultures.
[0168] Digestion of colorectal cancer tissue for tumor and T cell cultures. Tumor biopsies were cut into thin strips of approximately 1–2 mm. One strip was fixed in 4% formaldehyde for histological analysis, and one strip each was flash frozen (in dry ice or liquid nitrogen) and stored at −80°C for genetic and / or protein analysis. Forceps were used to further cut the remaining strips until the tumor mass appeared viscous. The tumor mass was incubated in 10 mL of complete Advanced DMEM / F12 medium containing 1 mg / mL collagenase II, 10 μg / mL hyaluronidase, and the Rho kinase inhibitor Y-27632 at 37°C for 1 h with shaking. After incubation, 2 mL of FCS was added to the slurry tumor mass, and the cell suspension was filtered through a 100-μm cell strainer and centrifuged at 300 × g for 5 min at 4°C. The supernatant was removed, and the cell pellet was washed twice with complete Advanced DMEM / F12 medium. Single cell suspensions were cryopreserved in liquid nitrogen in freezing medium (either Gibco™ Recovery™ Cell Culture Freezing Medium or 10% DMSO in a 1:1 mixture of FCS and Advanced DMEM / F12) or further processed for derivation of colorectal cancer tumoroids and T cell culture.
[0169] Derivation of colorectal tumoroid tumors. A fraction of the tumor single cell suspension was resuspended in BME and plated at different dilutions. 2 The BME was allowed to solidify for 30 min in a humidified incubator at 4 °C. Cells embedded in the BME were cultured in human colorectal cancer tumoroid medium supplemented with the Rho kinase inhibitor Y-27632. The medium was refreshed every 3–4 days. Organoids formed from single tumor cells were passaged every 7–10 days.
[0170] Example 4. Analysis of organoids and tumoroids. Brightfield optical microscopy was performed for analysis to confirm successful single cell suspension of organoid and tumouroid samples. Representative brightfield images of normal colon organoids and tumouroids derived from patient samples are shown in Figure 1B.
[0171] Colonic crypts were embedded in normal colon organoid medium (containing basement membrane extract (BME) and R-spondin-1, noggin, Wnt3A conditioned medium, vitamin A-free B27 supplement, nicotinamide, N-acetylcysteine, EGF, TGF-β inhibitor A-83-01, gastrin, p38 MAPK inhibitor SB202190, and prostaglandin E2) as described above. Normal colon organoids developed within 1 week and were passaged weekly thereafter (top panel).
[0172] Single cell suspensions from colorectal cancer samples were embedded in basement membrane extract (BME) and cultured in tumoroid medium (R-spondin-1, noggin-conditioned medium, vitamin A-free B27 supplement, nicotinamide, N-acetylcysteine, EGF, TGF-β inhibitor A-83-01, gastrin, p38 MAPK inhibitor SB202190, and prostaglandin E2). Tumoroids formed within 1 week and were passaged weekly thereafter (lower panel).
[0173] As can be seen in each panel of Figure 1B, single cell suspensions of well-separated organoids, tumoroids, and immune cells are achieved.
[0174] Example 5. Isolation of lymphocytes from single cell suspensions and T cell expansion cultures. In this example, further processing of immune cells and subsequent production of immune cell expansion cultures are demonstrated.
[0175] Five mL of pure Ficoll-Paque PLUS (GE Healthcare) was added to a 15 mL standard tube. Single cell suspensions obtained from digests of normal colon or colorectal cancer tissues were resuspended in 5 mL of complete RPMI 1640 medium and carefully placed on top of the clear Ficoll-Paque PLUS layer. Samples were centrifuged at 800 × g for 20 min at room temperature. Cells on top of the clear Ficoll-Paque PLUS layer, containing T cells, were collected, resuspended in 10 mL of complete RPMI 1640 medium and centrifuged at 300 × g for 5 min. Cell pellets were resuspended in complete RPMI 1640 medium and counted. Single cell suspensions were either frozen and stored in liquid nitrogen in freezing medium (either Gibco™ Recovery™ Cell Culture Freezing Medium or 10% DMSO in a 1:1 mixture of FCS and Advanced DMEM / F12) or used immediately for expansion cultures. For T cell expansion cultures, the cells were incubated at 37 °C and 5% CO 2 1 × 10 cells were plated in 1 mL of RPMI 1640 complete with penicillin / streptomycin, 5% human AB serum, and 6000 IU recombinant human IL-2 (Miltenyi) on anti-CD28 (Miltenyi)-coated cell culture plastic in a humidified incubator at 37 °C. 6 Lymphocytes were cultured at a total viable cell concentration and the medium was refreshed after 1 week.
[0176] Additionally or alternatively, peripheral blood is processed to purify peripheral blood mononuclear cells enriched for peripheral blood lymphocytes (PBLs) and T cells.
[0177] Primary analysis is performed by T cell receptor (TCR) sequencing and immunophenotyping of T cells (see FIG. 1C and Example 6 below).
[0178] Example 6. Analysis of isolated immune cells. FIG. 1C shows representative brightfield images of clonal expansion of intraepithelial lymphocytes (IELs) and tumor-infiltrating lymphocytes (TILs) derived from patient samples (left panel).
[0179] Flow cytometry analysis shows robust expansion of CD4+ T helper (Th) cells and CD8+ cytotoxic T cells (CTL). Single cell suspensions from normal colon mucosa or colorectal cancer tissues were maintained in T cell medium containing interleukin-2 (IL-2). Clonal expansion of T cells was evident within 1-2 weeks (left panel).
[0180] Thus, analysis of isolated immune cells reveals that they remain functional and biologically representative.
[0181] Example 7. Passage of epithelial organoids and tumoroids. This example demonstrates the maintenance of organoid and tumoroid cultures.
[0182] Organoid cultures were disrupted ("split") by pipetting a drop of BME up and down in growth medium using a 1 mL capacity micropipette (i.e., P1000 Gilson). Disrupted organoids were centrifuged at 500 x g for 5 min. Pelleted organoids were resuspended in TrypLE (Gibco™) and incubated at 37°C for 5-15 min in a water bath. Organoids were dissociated into single cells using a pre-wetted, flame-polished glass Pasteur pipette. Dissociated organoids were harvested in an excess of complete Advanced DMEM / F12 and centrifuged at 500 x g for 5 min. Epithelial single cells were replated at the desired density in BME and incubated at 37°C and 5% CO. 2 The plates were placed in a humidified incubator at 37 °C. When the BME solidified, the respective culture medium (either human colon organoid medium or human colorectal cancer tumoroid medium) supplemented with the Rho kinase inhibitor Y-27632 was added. The medium was refreshed every 3–4 days. Organoids formed from single tumor cells were passaged every 7–10 days.
[0183] Primary analysis is performed by single-cell messenger RNA (mRNA) sequencing of cells present in single cell suspensions of normal colonic and tumor epithelium.
[0184] Example 8. Production of organoid and tumoroid co-cultures. This example demonstrates the co-culture of organoids and tumorigenesis cells from Example 5 with immune cell cultures from Example 4.
[0185] Upon splitting, 5000 cells were seeded onto BME (as in Example 7 above) and cultured for 3-4 days in either human colon medium or human colorectal tumorigenesis medium. Upon culture, the medium was removed and following incubation on ice for 25 minutes, the BME / Matrigel droplets were disrupted using Cell Recovery Solution™ (Corning). Cells were subsequently centrifuged (500×g for 5 minutes) and resuspended in T cell medium supplemented with 100 IU / mL recombinant human IL-2 before mixing with T cells.
[0186] T cells were counted and brought to a concentration of 100000 cells / mL in complete T cell medium supplemented with 100 IU / mL recombinant human IL-2. 100 μL of epithelial carcinoma tumoroid suspension was mixed with 100 μL of T cell suspension in a 96-well plate. 22 μL of rat tail collagen (Gibco™) was dissolved in the mixture to reach a concentration of 10% collagen in the suspension. Cells were incubated at 37°C and 5% CO 2 The plates were then incubated at RT for 30 min to allow the cells and collagen to settle before analysis.
[0187] A proof-of-principle co-culture of normal colon organoids and allogeneic CD3+ T cells in droplets of basement membrane extract (BME) is shown in Figure 2.
[0188] Figure 2A shows a schematic of the procedure. Normal colon organoids were released from the BME droplets using Cell Recovery Solution and washed with complete Advanced DMEM / F12 as described above. Expanded CD3+ T cells were harvested from the cultures and labeled with green dye (Vybrant CFDA SE Cell Tracer). Colon organoids and labeled T cells were mixed in human colon organoid medium and embedded into BME droplets. Co-cultures were maintained for 60 hours in human colon organoid medium with IL-2. Co-cultures were released from the BME using Cell Recovery Solution and fixed in 4% paraformaldehyde. Fixed whole tissue specimens were stained with phalloidin to mark polymerized actin and DAPI to label nuclei. Whole tissue specimens were mounted onto slides in ProLong Gold antifade mounting medium and imaged on a Leica SP8X confocal microscope.
[0189] Maximum projections of z-stack images of colonic organoid co-cultures are shown in Figure 2B. F-actin in the organoids is labeled in dark grey, and T cells are labeled in light grey. The inset in the right panel shows T cells infiltrating the colonic epithelium.
[0190] Three-dimensional reconstruction of normal colon organoids and T cells is shown in Figure 2C.
[0191] As can be seen, the organoids display the expected level of structural organization and interact with immune cells with striking similarity to in vivo systems.
[0192] Example 9. Analysis of co-cultures by imaging, flow cytometry, and cytokine secretion. In this example, the organoid and tumoroid co-cultures produced in Example 6 are analyzed to investigate the mechanisms by which the co-culture components interact.
[0193] Imaging analysis. Imaging analysis is used to determine the percentage of dying cells in the co-cultures.
[0194] Prior to culture, T cells were labeled with a cell tracking dye (e.g., CFSE, Molecular Probes™). Organoids were labeled with directly conjugated mouse anti-human EPCAM (BD Bioscience) antibodies or with a cell tracking dye (different from that for T cell labeling). Using a confocal laser scanning microscope (e.g., Leica SP8X; or any kind of live cell imaging time-lapse fluorescence microscope), cells were incubated at 37°C and 5% CO in the presence of a dye (e.g., NucRed Dead™, Molecular Probes) to mark apoptotic cells. 2 The organoids were imaged overnight (12–18 h) at 4°C for 1 h. Time-lapse images were subsequently analyzed using Imaris software (Bitplane) to calculate the percentage of dying organoids by assessing the percentage of voxels in which EPCAM colocalization and dead cell markers could be visualized.
[0195] Flow cytometry analysis Flow cytometric analysis is used to assess surface markers present on immune cells present in the co-cultures.
[0196] Upon splitting, 5000 cells were seeded onto BME (as in Example 7 above) and cultured for 3-4 days in either human colon medium or human colorectal tumorigenesis medium. Upon culture, the medium was removed and following incubation on ice for 25 minutes, the BME / Matrigel droplets were disrupted using Cell Recovery Solution™ (Corning). Cells were subsequently centrifuged (500×g for 5 minutes) and resuspended in T cell medium supplemented with 100 IU / mL recombinant human IL-2 before mixing with T cells.
[0197] T cells were counted and brought to a concentration of 500000 / mL in complete T cell medium supplemented with 100 IU / mL recombinant human IL-2. 100 μL of epithelial cancer tumoroid suspension was mixed with 100 μL of T cell suspension in a 96-well plate. Cells were co-cultured overnight, harvested, and single cell suspensions were made using TripLE (Gibco™). Single cell suspensions were fixed with 4% paraformaldehyde (Sigma-Aldrich) and permeabilized using a buffer containing 0.5% saponin (BD Bioscience). Alternatively, a commercially available kit (e.g., BD Cytofix / Cytoperm Plus Fixation / Permeabilization Kit, BD Bioscience) was used. Subsequently, cells were incubated with flow cytometry antibodies against CD3, EPCAM, interferon (IFN)γ, and / or tumor necrosis factor (TNF)α (all from BD Bioscience) together with an antibody recognizing activated caspase-3, followed by flow cytometry analysis.
[0198] Cytokine secretion analysis. Organoids were split, seeded, cultured, and prepared for co-culture as described above. T cells were counted and brought to a concentration of 500000 / mL in complete T cell medium supplemented with 100 IU / mL recombinant human IL-2. 100 μL of epithelial cancer tumoroid suspension was mixed with 100 μL of T cell suspension in a 96-well plate. 72 hours after the initiation of culture, supernatants were harvested for evaluation of T cell cytokine production (e.g., IFNγ, TNFα) by ELISA. Culture supernatants were stored at -20°C until analysis.
[0199] Example 10. Live imaging of tumoroid co-cultures shows increased T cell motility when co-cultures are made with rat tail collagen I. In this example, the effect of different structural components used in the development of co-cultures on the resulting motility of immune cells is examined.
[0200] A schematic of the procedure is shown in Figure 3A. Tumoroids were released from the BME droplets using Cell Recovery Solution and washed with complete Advanced DMEM / F12, as described above. Allogeneic CD8+ T cells isolated from peripheral blood samples were labeled with green dye (Vybrant CFDA SE Cell Tracer).
[0201] Tumoroids and T cells were mixed with human colon organoid medium containing IL-2 and either 10% BME or rat tail collagen I and incubated at 37 °C and 5% CO 2 The cells were live-imaged for 80 h on a Leica SP8X confocal microscope equipped with a live imaging chamber at 37 °C.
[0202] Figure 3B shows a representative composite image of a tumorigenesis coculture. The bright field and green fluorescent channels were integrated into the composite image produced. The migration path of T cells was tracked using Imaris software.
[0203] Quantification of T cell trajectory length in both conditions shows significantly longer trajectory paths for T cells co-cultured in 10% collagen compared to 10% BME, as graphed in Figure 3C. The results suggest that the use of rat tail collagen I in co-culture produces longer trajectories, thus preserving immune cell motility and allowing the development of a more in vivo-like system.
[0204] Example 11: Generation of clonal tumorigenetic co-cultures. This example illustrates the generation of clonal tumorigenesis positive and negative for human leukocyte antigen (HLA) type A2.
[0205] A schematic of the procedure is shown in Figure 4A. Tumoroids were dissociated into single cells using TrypLE enzyme digestion. Single cells were stained with anti-HLA-A2 antibody and purified based on anti-HLA-A2 immunoreactivity. HLA-A2+ve and HLA-A2-ve tumor cells were embedded and maintained to produce tumoroids.
[0206] Flow cytometry analysis in Figure 4B shows the establishment of pure HLA-A2+ve or HLA-A2-ve tumoroid lines. Controls are HLA-A2+ve JY cell lines and normal colon organoid lines derived from the same patient samples as the HLA-A2+ve or HLA-A2-ve tumoroid lines.
[0207] Example 12. Assay of cytotoxic T cell-mediated antigen-specific killing of epithelial carcinoma tumorigenesis. This example involves performing a "cell killing assay" on tumoroid co-cultures, which is an example of the method of the invention applied to neoantigen-experienced αβ T cells to treat cancer.
[0208] Colorectal cancer tumoroids or normal tissue organoids were split and kept as single cells as described above. 10,000–50,000 T cells (TIL or PBMC derived) were co-cultured with 50,000 tumoroid / organoid derived single cells in the presence of stimulatory αCD28 antibody for 2 weeks in human T cell medium and 200 IU / mL recombinant human IL-2. Medium was refreshed every 2–3 days. Subsequently, expanded cells were cultured on irradiated feeder cells (1 × 10 6 / mL, PBMCs from three different donors and 1 × 10 5 / mL mixture of JY and / or LAZ509 cells. Alternatively, the cells were clonally expanded in the presence of (1 × 10 6 / mL, PBMCs from three different donors and 1 × 10 5T cells were FACS-sorted directly from TIL or IEL single-cell preparations into plates containing 100 μg / mL JY and / or LAZ509 cell mixes. Expanded clones were then co-cultured with tumor organoids that were subsequently pulsed with neoantigens as described above.
[0209] Identified putative tumor neoantigens were loaded onto epithelial cancer organoids as follows: The BME / Matrigel® droplets in which the organoids were cultured were disrupted by resuspending the medium in the plate. Relevant peptides were added to the organoids and the organoids were incubated at 37° C. and 5% CO 2 Clonally expanded T cells were then co-cultured with autologous organoids for imaging, flow cytometry, and / or cytokine secretion analysis, as described above.
[0210] A killing assay for anti-tumoroid reactivity of antigen-experienced T cells is shown in Figure 5, and a schematic diagram of the procedure is shown in Figure 5A. HLA-A2+ve or HLA-A2-ve tumoroids were pulsed with HLA-A2-restricted Wilms' tumor (WT) 1 peptide for 2 h. Then, TCR-transgenic CD8+ T cells harboring WT1 peptide-specific TCR were co-cultured with HLA-A2+ve or HLA-A2-ve tumoroids pulsed with WT1 peptide for 48 h.
[0211] Representative brightfield images of the co-cultures after 48 hours are shown in Figure 5B. Significant death is observed for HLA-A2+ve tumoroids pulsed with WT1 peptide alone. All other conditions, i.e., HLA-A2+ve or HLA-A2-ve tumoroids not pulsed with WT1 peptide, and HLA-A2-ve tumoroids pulsed with WT1 peptide, show normal growth.
[0212] The results suggest that the neoantigen WT1 peptide is effective in killing tumorigenesis (and possibly treating cancer) in tumorigenesis with an HLA-A2+ve phenotype, but not for other phenotypes.
[0213] Example 13. Cell viability assay for anti-tumoroid reactivity of antigen-experienced T cells with and without checkpoint inhibition. A cell viability assay for antitumoroid reactivity of antigen-experienced αβ T cells with and without checkpoint inhibition is shown in Figure 6. This is an example of the method of the present invention applied to chemical agents to treat cancer.
[0214] A schematic of the procedure is shown in Figure 6 A. Cocultures were performed as described in Figure 5 A, but for 12 h only, with and without anti-PD1 checkpoint inhibitors. Cell viability assays were performed using the CellTiter Glo Luminescent Cell Viability Assay kit (Promega) according to the manufacturer's instructions.
[0215] Figure 5B shows the cell viability of tumorigenesis normalized to the no peptide control. Thus, we have successfully used co-cultures to demonstrate that tumorigenesis cell viability was lowest when the combination of HLA-A2, IL-2, and anti-PD1 checkpoint inhibitors was present, i.e., anti-PD1 checkpoint inhibitor treatment may be most potent when applied to the subpopulation of patients presenting with IL-2 and HLA-A2 cancer types.
[0216] Example 14. Assay to determine the differential effects on T cell activation by organoid / tubulin co-cultures. This example illustrates that the presence of γδ T cells does not activate organoids in co-culture above baseline levels without T cells, but does activate organoids in co-culture in an antigen-nonspecific manner. Activation was determined using IFN-γ.
[0217] A schematic diagram of the procedure is shown in Figure 7A. Tumoroids were released from the Matrigel® droplets using Dispase and subsequently passed through 70 μm and 20 μm filters. Organoids were harvested from the 20 μm filter, counted, and plated. Tumoroids and T cells were mixed with human colon organoid medium containing RPMI, IL-2, and 5% Matrigel® and incubated at 37°C and 5% CO. 2 After 24 h of incubation, the organoids were imaged using a bright-field inverted microscope.
[0218] Representative brightfield images of tumoroid and organoid co-cultures are shown in Figures 7B and 7C (respectively).
[0219] Quantified IFN-γ levels in the co-cultures are shown in Figure 7D.
[0220] Example 15. Live imaging of tumorigenesis co-cultures to assess association and cell killing capacity. T cells were investigated for their cell killing capacity as well as variations in T cells due to different T cell subtypes and for different T cell / tumor antigen combinations.
[0221] A schematic of the procedure is shown in Figure 8A. Tumoroids were released from the Matrigel® droplets using Dispase and subsequently passed through 70 μm and 20 μm filters. Organoids were harvested from the 20 μm filters, counted, and plated. Cultured T cells labeled with far-red dye (CellVue Claret). Tumoroids and T cells were mixed with human colon organoid medium containing RPMI, IL-2, and 5% Matrigel® and incubated at 37°C and 5% CO. 2 The cells were live-imaged for 68 h on a Leica SP8X confocal microscope equipped with a live imaging chamber at 37 °C.
[0222] A representative composite image of a tumorigenesis co-culture with non-targeting T cells is shown in Figure 8B. The bright field and far-red fluorescent channels were integrated into the composite image produced.
[0223] A representative composite image of a tumorigenesis co-culture with target T cells is shown in Figure 8 C. The bright field and far-red fluorescent channels were integrated into the composite image produced.
[0224] Example 16. Modeling cancer immune regulation using epithelial organoid cultures. Here, we utilize organoid technology to study immune-cancer interactions and evaluate immune modulation by colorectal cancer (CRC). Transcriptional profiling and flow cytometry revealed that organoids maintained differential expression of immune regulatory molecules present in primary tumors. Finally, we established a method to model antigen-specific epithelial cell killing and cancer immune modulation in vitro using CRC organoids co-cultured with cytotoxic T cells (CTLs).
[0225] CRC is one of the most common cancers worldwide. Early stages of CRC are highly treatable by surgical resection, whereas later stages are usually incurable. CRC originates from small lesions in the colon epithelium through a multi-step process. These lesions grow into adenomas with low-grade dysplasia, progress to high-grade dysplasia, and finally result in invasive carcinoma. Genetic mutations in signaling pathways, such as the canonical pathway of Wnt signaling, are the molecular basis of CRC4. However, the interaction of tumors with their microenvironment is another defining hallmark. Cancer cells remodel their microenvironment (e.g., fibroblasts, vasculature, and immune cells) to support tumor growth. Infiltrating immune cells (ICs), such as CTLs or macrophages, play a pivotal role by producing distinct immune responses, such as antitumor cytotoxicity (the former) or tumor-promoting chronic inflammation (the latter). Thus, escape from the surveilling immune system is recognized as one of the hallmarks of cancer. Cancer cells undergo a process called immunoediting to quell antitumor responses by preventing T cell activation through the stimulation of inhibitory cell surface receptors, such as CTL-associated antigen (CTLA)-4 or programmed death (PD)1. Overcoming this active immune regulation by tumor cells has become a major therapeutic target. However, tumor heterogeneity, such as differential infiltration of CTLs or differential expression of immune inhibitors, can affect the therapeutic efficiency of antitumor drugs by mediating drug resistance. Therefore, it is of great importance to develop ex vivo model systems that characterize the communication between tumors and their environment. Organoid cultures grown from different epithelial tissues serve as excellent tools to study tissue homeostasis and diseases. Moreover, organoid biobanks of multiple epithelial organ systems have been established, and tumor-derived organoids have been successfully used as a platform to screen different drugs and predict patient responses. Here, we describe the establishment of a method to model antigen-specific epithelial cell killing and immune regulation of cancer in vitro using organoids co-cultured with immune cells (specifically, CRC organoids co-cultured with CTLs).
[0226] We first evaluated whether CRC organoids express immune-modulating molecules in established long-term cultures.To this end, we used the transcriptome dataset generated with our "living organoid biobank" of CRC patients to compare the gene expression of T cell-specific immune-modulating substances in CRC organoids with the expression levels found in normal colon organoids (van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945, doi:10.1016 / j.cell.2015.03.053 (2015)).On average, the transcription of genes related to T cell stimulation, such as TNFSF4 or TNFSF9, was not altered in CRC organoids compared to normal colon organoids) Figure 9A. However, expression of human leukocyte antigen (HLA) genes HLA-A and HLA-C, which code for major histocompatibility complex class (MHC)-I molecules that present antigens to T cells, was significantly downregulated in CRC organoids (Figure 9A), a well-described phenomenon found in cancer. Expression of genes related to inhibition of T cell function was either significantly upregulated, such as BTLA, significantly downregulated, such as CD80, CD86, LGALS9, or not altered at all, such as CD274 (encoding PD-L1) and PDCD1LG2 (encoding PD-L2) (Figure 9A). When expression levels of immune regulatory molecules in individual organoids were evaluated, CRC organoids were predominantly clustered, showing heterogeneous downregulation of HLA-A, HLA-C, and LGALS9 compared to healthy colon organoids (Figure 9B). However, expression of the immune inhibitory genes CD274 and PDCD1LG2, for example, was highly upregulated in some CRC organoids compared to matched normal colon organoid cultures, reflecting the previously reported preservation of tumor heterogeneity in organoids (Figure 9B).These molecular signatures provide a basis for further investigation of tumor immunogenicity and its association with other features of tumors.
[0227] Four of the most commonly mutated genes in CRC are APC, P53, KRAS, and SMAD4, reflecting the stepwise progression of normal intestinal epithelium to metastatic cancer. We demonstrated that the introduction of these cancer mutations into human intestinal organoid cultures using clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 can mimic this process in vitro and upon xenografting into mice. Using colon organoids harboring one or more of these cancer mutations, we investigated whether upregulation of PD-L1 is associated with specific mutational status. Furthermore, we exposed mutant organoids and their wild-type control organoid lines to interferon (IFN)-γ, which is secreted by T cells and can induce increased expression of immune regulatory molecules such as PD-L1. Subsequently, we assessed PD-L1 expression by quantitative polymerase chain reaction (qPCR) and flow cytometry (Figure 9C-D). In the absence of IFN-γ, the triple mutant (APC KO / KO ,P53 KO / KO , KRAS G12D / + ) and quadruple mutations (APC KO / KO ,P53 KO / KO , KRAS G12D / + , and SMAD4 KO / KO ) exhibited lower CD274 gene expression compared to control wild-type organoids (Figure 9C). Overall, PD-L1 expression was low in untreated organoid lines (Figure 9C-D). However, in organoids treated with IFN-γ, PD-L1 expression was dramatically upregulated at both the transcript and protein levels (Figure 9C-D). These data demonstrate that CRC organoids express immune modulators and that this expression is regulated in a manner similar to that previously shown for in vivo tissues.
[0228] Next, we aimed to establish a co-culture system of CRC organoids and CTLs to model antigen-specific killing of tumor cells in vitro. For this, we used αβ T cells carrying a transgenic T cell receptor (TCR) that recognizes HLA-A2-restricted Wilms' tumor (WT) 1-derived peptide. We first used flow cytometry to screen CRC organoids from the "living biobank" and newly produced CRC organoids for HLA-A2 expression. We found three CRC organoid lines that showed partial downregulation of HLA-A2 (Figure 4B). We found that HLA-A2 expression was significantly downregulated by CTLs in the 3 CRC organoids. + and HLA-A2 - CRC organoids could be purified and cultures were successfully established from both populations (Figure 11B). We found that IFN-γ stimulation did not induce HLA-A2 re-expression and that HLA-A2 - We confirmed that MHC-I was stably downregulated in CRC organoids (Fig. 10B). We then pulsed these CRC organoid lines with WT1 peptide and subsequently co-cultured them with peptide-specific T cells for 48 hours. Following co-culture, we found that HLA-A2 - We found that CRC organoids survived regardless of whether they were pulsed with peptide (Figure 11C). However, HLA-A2 without prior peptide incubation + Only CRC organoids survived in co-culture. Figure 11C. Peptide-pulsed HLA-A2 + CRC organoids were effectively killed by peptide-specific T cells, providing proof of principle that organoids can be used to study antitumor responses by cytotoxic T cells in vitro. To further confirm the antigen specificity of our "killing" assay system, we cross-linked HLA-A2 with a construct expressing mNeonGreen-tagged histone H2B. +We improved our co-culture method by transfecting CRC organoids and staining T cells with CellTracker violet to allow long-term tracking of both cell types (Methods, below). We then transfected HLA-A2 T cells with either WT1 peptide or EBV-derived peptide (Methods). + We pulsed CRC organoids and co-cultured them with T cells bearing either WT1 or EBV-specific TCR. Here, only organoids pulsed with the cognate peptide were efficiently killed by T cells (Fig. 11D). Enzyme-linked immunosorbent assay (ELISA) was used to test IFN-γ production by T cells in the co-culture, confirming antigen-specific organoid killing by T cells (Fig. 11E). To better follow the kinetics of organoid killing, we applied a fluorescent dye that specifically stains apoptotic cells (NucRed Dead 647; Methods) and performed live confocal imaging on the co-cultures (Fig. 11F). Next, we quantified organoid killing by assessing the co-localization of NucRed Dead dye with H2B-mNeonGreen (Methods). Significant co-localization of both labels, i.e., organoid killing, was consistent with the results of peptide-pulsed HLA-A2 +This was only observed when CRC organoids were co-cultured with the respective peptide-specific T cells, Figure 11G. Moreover, T cell infiltration into the epithelium of the organoids could be easily detected in this co-culture condition, Figure 11H. Finally, we investigated whether this co-culture system could be used to model the modulation of the immune response against immunosuppressive tumors. Indeed, the addition of a blocking antibody against PD-1 (αPD-1) enhanced tumor killing and IFN-γ production in PD-L1-expressing IFN-γ-stimulated organoids, Figure 11I-J. This was not observed when the organoids were not stimulated with IFN-γ and therefore did not express PD-1. In conclusion, T cells efficiently killed co-cultured CRC organoids in an antigen-specific manner. Moreover, we were able to model the inhibition of T cells and the subsequent relief of this inhibition using αPD-1. Here, we demonstrated that epithelial organoids can be used to faithfully recapitulate the interaction between tumor tissue and the immune system. Using our co-culture assay, we also set up a first step to reconstruct the tumor microenvironment in vitro. Further addition of other components of this microenvironment (fibroblasts, natural killer cells, myeloid-derived suppressor cells, B cells, etc.) may reveal the complex interactions between different cell types that lead to tumor immune evasion. Finally, this co-culture system can be used as a tool for drug screening to test the applicability of specific immunotherapies, such as chimeric antigen receptor (CAR) or TCR transgenic T cells, antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP), in different tumors and different patients, inducing tumor-directed antibodies.
[0229] Methods Human materials and informed consent Colon tissues (both normal colon and tumor tissue) were obtained from the Department of Surgery and Pathology of the Diakonessenhuis Hospital, Utrecht, The Netherlands. All patients included in this study were diagnosed with CRC. All patients included signed informed consent. Tissue collection was approved by the Medical Ethics Committee (METC) of the Diakonessenhuis Hospital, in accordance with the Declaration of Helsinki and in accordance with Dutch and European Union legislation.
[0230] Organoid generation and culture Epithelial organoid lines were derived from healthy colon or tumor tissue (van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945, doi:10.1016 / j.cell.2015.03.053 (2015)). Briefly, chelating solution (5.6 mM Na 2 SO 4 ) supplemented with dithiothreitol (0.5 mM, Sigma) and EDTA (2 mM, in-house) was used to culture the organoids. 2 HPO 4 , 8.0 mM KH 2 PO 4Healthy colonic crypts were isolated by digesting colonic mucosa in 10 mM NaCl, 96.2 mM NaCl, 1.6 mM KCl, 43.4 mM sucrose, and 54.9 mM D-sorbitol (Sigma) for 30 min at 4°C. Subsequently, colonic crypts were plated in basement membrane extract (BME; Cultrex PC BME RGF type 2, Amsbio) and organoids were grown in human intestinal stem cell medium (HISC) composed of Advanced Dulbecco's modified Eagle's medium / F12 supplemented with penicillin / streptomycin, 10 mM HEPES, and Glutamax (all Gibco, Thermo Fisher Scientific) and 50% Wnt3a-conditioned medium (in-house), 20% R-spondin1-conditioned medium (in-house), 10% Noggin-conditioned medium (in-house), 1x B27, 1.25 mM n-acetylcysteine, 10 mM nicotinamide, 50 ng / mL human EGF, 10 nM gastrin, 500 nM A83-01, 3 μM SB202190, 10 nM prostaglandin E2, and 100 μg / mL primocin (Invivogen). Tumor specimens were digested into single cells in collagenase II (1 mg / mL, Gibco, Thermo Scientific) supplemented with hyaluronidase (10 μg / mL) and LY27632 (10 μM) for 30 minutes at 37°C with shaking. Single tumor cells were seeded on BME, and organoids were cultured at 37°C in HICS without Wnt-conditioned medium supplemented with 10 μM LY27632. When we refer to the "in-house" components of the medium, those skilled in the art will readily have commercially available alternatives (e.g., Wnt agonist (ATCC CRL 2647™), R-spondin (R&D, #3500-RS / CF), Noggin (Peprotech, #120-10C), EDTA (Thermo fisher, #AM9260G)) and will understand that these achieve the same or equivalent effect.
[0231] Tumoroid transfection Tumoroids (specifically, CRC organoids) were dissociated into small clumps using TrypLE and then transduced with H2B-mNeonGreen (pLV-H2B-mNeonGreen-ires-Puro).
[0232] T cells The generation of αβ T cells bearing a transgenic TCR recognizing HLA-A2-restricted WT1-derived peptide was described in Kuball, J. et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109, 2331-2338, doi:10.1182 / blood-2006-05-023069 (2007). Briefly, TCR α and β chains were cloned from grown tetramer-positive T cell clones. Subsequently, retroviral supernatants from Phoenix-Ampho packaging cells transfected with gag-pol, env, and pBullet retroviral constructs containing the cloned TCR genes were used to generate CD8 T cells. + αβTCR T cells were transduced.
[0233] Co-culture and live cell imaging of tumorigenetic T cells Five to seven days prior to co-culture, tumorigenesis stably transfected with H2B-mNeonGreen was split and digested and seeded at a density of 5000 cells per 10 µL of BME (25,000 cells per well in a 12-well cell culture plate). Two days prior to co-culture, T cells were starved of IL-2. One day prior to co-culture, tumorigenesis was stimulated with the indicated concentrations of IFN-γ.
[0234] Prior to co-culture, T cells were stained with Cell Proliferation Dye eFluor 450 (eBioscience) according to the manufacturer's instructions. Prior to co-culture, tumoroids were pulsed with a TCR-specific peptide (ProImmune) for 2 h at 37 °C. Tumoroids and T cells were harvested and collected in T cell medium supplemented with 10% BME, 100 IU / mL IL-2, and NucRed Dead 647 (Thermo Fischer). Where indicated, anti-PD1 blocking antibodies (2 μg / mL) were added to the co-culture. Cells were seeded in glass-bottom 96-well plates, and co-cultures were imaged using an SP8X confocal microscope (Leica).
[0235] Flow cytometry Using APC-labeled pentamers against the EBV-derived HLA-2:02-restricted peptide FLYALALLL (ProImmune), pentamers were isolated from PBMCs isolated from buffy coats from healthy individuals. + CD8 + CD3 + T cells were sorted. Cells were sorted as single cells into 96-well plates using a BD FACS Aria (BD Biosciences) hemocytometer. For flow cytometry, the following antibodies were used (all anti-human): CD8-PE (clone RPA-T8), CD45-PerCP-Cy5.5 (2D1), CD274 (PD-L1)-APC (MIH1) (all BD Biosciences), CD279 (PD-1)-PE (EH12.2H7, Biolegend), HLA-A2-PE (BB7.2, Santa Cruz).
[0236] Quantitative polymerase chain reaction (qPCR) For qPCR analysis, RNA was isolated from organoids / tuboloids using the RNAeasy kit (QIAGEN) according to the manufacturer's procedure. PCR analysis was performed using SYBR Green Reagent (Biorad). PCR reactions were performed in duplicate with standard curves for all primers. Primers were designed using the NCBI primer design tool. Primers used in this study: TIFF2024045127000001.tif27162.
[0237] Transcriptional profiling Microarray analysis of biobanked organoids was performed as described in van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945, doi:10.1016 / j.cell.2015.03.053 (2015).
[0238] Enzyme-linked immunosorbent assay (ELISA) Culture supernatants were kept at −20°C, and ELISAs were performed for the indicated cytokines using ELISA MA Standard (Biolegend) according to the manufacturer's procedures.
[0239] Cell viability assay Cell viability after coculture was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer's procedure.
[0240] Image analysis Image analysis was performed using the Imaris software package (Bitplane). Briefly, a threshold for positive staining was set based on the negative control. Colocalization channels were generated for H2B-neon and NucRed Dead 647 signals. Cell death was quantified as the percentage of H2B-mNeonGreen+ voxels colocalizing with the NucRed Dead signal.
[0241] Bioinformatics analysis Bioinformatics analysis of normalized gene expression data from microarray experiments (van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945, doi:10.1016 / j.cell.2015.03.053 (2015)) was performed using standard packages (i.e., gplots) in R version 3.4.0 (R Foundation, https: / / www.r-project.org) and RStudio version 1.0.143 (https: / / www.rstudio.com).
[0242] statistical analysis All experiments were repeated at least three times unless otherwise stated. All data are presented as mean ± SEM. Statistical significance was analyzed by either ANOVA or two-tailed Student's t-test using either Graphpad Prism 6 or Microsoft Excel 2010.
[0243] Sequence information SEQUENCE LISTING <110> KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN HUB ORGANOIDS IP BV <120> IMMUNE CELL ORGANOID CO-CULTURES <150> GB 1721615.1 <151> 2017-12-21 <160> 7 <170> SeqWin2010, version 1.0 <210> 1 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Forward Primer <400> 1 gtcggagtca acggatt 17 <210> 2 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Reverse Primer <400> 2 aagcttcccg ttctcag 17 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> HPRT Forward Primer <400> 3 ggcgtcgtga ttagtgat 18 <210> 4 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> HPRT Reverse Primer <400> 4 agggctacaa tgtgatgg 18 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> CD274 Forward Primer <400> 5 tgcagggcat tccagaaaga t 21 <210> 6 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> CD274 Reverse Primer <400> 6 ccgtgacagt aaatgcgttc ag 22 <210> 7 <211> 15 <212> DNA <213> Unknown <220> <223> unknown sequence <400> 7 cagctgtagc tacgt 15
Claims
1. A method for identifying an agent suitable for treating irritable bowel disease (IBD), comprising: contacting the organoid co-culture with one or more candidate agents, wherein the organoid co-culture comprises immune cells and at least one organoid; Detecting the presence or absence of one or more changes in the organoid co-culture that indicate the suitability of the candidate agent for the treatment of irritable bowel disease; Identifying the candidate agent as suitable for treating irritable bowel disease when the presence or absence of one or more of said alterations is detected in said organoid co-culture.
2. (a) Suitability for the treatment of irritable bowel disease includes efficacy for the treatment of irritable bowel disease and / or safety for the treatment of irritable bowel disease; (b) the one or more alterations are alterations in one or more irritable bowel disease biomarkers; (c) the one or more changes are selected from reduced cell viability, reduced cell proliferation, increased cell death, altered cell or organoid size, altered cell motility, altered production of cytokines and cytotoxic molecules by co-cultured immune cells, dissociation or destruction of an intact / dense epithelial cell layer, and altered expression of one or more genes; (d) detection comprises cell proliferation assays, viability assays, flow cytometry analysis, ELISA for IFN-γ, gene expression analysis, and / or cell imaging; (e) the one or more changes is a reduction in cell viability as detected, for example, by a CellTiter Glo Luminescent Cell Viability Assay kit (Promega), intracellular flow cytometry staining for active caspase 3 (BD), or positive staining of dead cells; (f) the one or more changes is increased cell death, e.g., as detected by bright field imaging; and / or (g) one or more of the following steps: Preparing at least one organoid by culturing epithelial cells in an organoid culture medium; preparing immune cells by isolating the immune cells from an impure immune sample and culturing the immune cells in an immune cell growth medium; and / or Preferentially, removing the organoid culture medium from at least one organoid and mixing said at least one organoid with immune cells in an organoid co-culture medium to prepare an organoid co-culture. is preceded by, 2. The method of claim 1.
3. The method of claim 1 or 2, comprising comparing the presence or absence of one or more changes in the organoid co-culture to a reference organoid, and further comprising: contacting a reference organoid co-culture with one or more candidate agents, wherein the reference organoid co-culture comprises immune cells and at least one reference organoid; and Detecting the presence or absence of one or more changes in the reference organoid co-culture that indicate the suitability of the candidate agent for the treatment of irritable bowel disease.
4. (a) if the presence or absence of an alteration is detected in the organoid co-culture but not in the reference organoid co-culture, the candidate agent is identified as a suitable agent; (b) one or more of the following steps: Preparing at least one reference organoid by culturing normal epithelial cells in an organoid culture medium; preparing immune cells by isolating the immune cells from an impure immune sample and culturing the immune cells in an immune cell growth medium; and / or Preferably, the method comprises removing the organoid culture medium from the reference organoid and subsequently mixing at least one reference organoid with immune cells in an organoid co-culture medium to prepare a reference organoid co-culture, Optionally, the impure immune sample is normal colon tissue and / or peripheral blood; and / or (c) A reference organoid co-culture is used as a control, preferably as a negative control; 4. The method of claim 3.
5. A method described in any one of claims 2 to 4, wherein (i) the organoid co-culture medium and / or (ii) the reference organoid co-culture medium comprises an extracellular matrix, preferably selected from collagen or any animal-derived or synthetic basement membrane matrix, and optionally, the collagen is rat tail collagen I.
6. A method described in any one of claims 1 to 5, wherein the co-culture contains at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, or at least 10% collagen, preferably the co-culture contains about 10% (v / v) collagen.
7. The method of any one of claims 2 to 6, wherein (i) the organoid co-culture medium and / or (ii) the reference organoid co-culture medium has a protein concentration of 0.15 mg / (ml Matrigel®) to 0.95 mg / (ml Matrigel®) for a Matrigel® concentration of 2% to 10%.
8. An organoid co-culture medium described in any one of claims 2 or 4 to 7. (a) immune cells of the organoid co-culture and / or the reference organoid co-culture have a motility of at least 40 μm / day, 60 μm / day, 80 μm / day, 100 μm / day, 120 μm / day, or 140 μm / day; (b) at least 20%, at least 30%, at least 40%, or at least 50% of the immune cells in the organoid co-culture and / or the reference organoid co-culture are capable of migrating a distance of at least 200 μm, at least 250 μm, at least 300 μm, at least 350 μm, or at least 400 μm in 80 hours; (c) the immune cells remain active for at least 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, or 72 hours; and / or (d) the one or more candidate agents have a known suitability for treating irritable bowel disease, the method further comprising identifying the one or more candidate agents as suitable agents for treating irritable bowel disease in a particular patient. The method according to any one of claims 1 to 8.
10. A method described in any one of claims 3 to 9, wherein both the organoid co-culture and the reference organoid co-culture are derived from a specific patient.
11. The method of claim 9 or 10, further comprising treating the patient with a candidate agent identified as suitable for treating irritable bowel disease in a particular patient.
12. (a) the one or more candidate agents are selected from one or more of the following therapeutic classes: immunotherapeutics, alkylating agents, antimetabolites, metabolic agonists, metabolic antagonists, plant alkaloids, mitotic inhibitors, topoisomerase inhibitors, radiotherapeutics, chemotherapeutics, antibodies, photosensitizers, transplanted stem cells, vaccines, cytotoxic agents, cytostatic agents, tyrosine kinase inhibitors, proteasome inhibitors, cytokines, interferons, interleukins, intercalating agents, targeted therapy agents, small molecule drugs, hormones, steroids, cellular therapeutic agents, viral vectors, and nucleic acid therapeutic agents; and / or (b) one or more candidate agents are immunotherapeutic agents; The method of any one of claims 1 to 11.
13. A method described in any one of claims 1 to 9, wherein one or more candidate agents have unknown suitability for the treatment of irritable bowel disease, and the method further comprises identifying a subset of the one or more candidate agents as suitable agents for the treatment of irritable bowel disease.
14. A method described in any one of claims 1 to 9 or 13, wherein one or more candidate agents have known suitability for treating a first irritable bowel disease and unknown suitability for treating a second irritable bowel disease, and the method further comprises identifying a subset of the one or more candidate agents as suitable agents for treating the second irritable bowel disease.
15. (a) the sample is a tissue biopsy; (b) the epithelial cell is an intestinal cell, e.g., a colorectal cell; (c) the epithelial cells are epithelial stem cells, preferably characterized by Lgr5 expression; (d) the immune cells comprise one or more cell types selected from the group consisting of intraepithelial lymphocytes (IELs), tumor infiltrating lymphocytes (TILs), peripheral blood mononuclear cells (PBMCs), peripheral blood lymphocytes (PBLs), T cells, and cytotoxic T lymphocytes (CTLs), αβ T cells, γδ T cells, B cells, NK cells, and mononuclear phagocytes; (e) immune cells are obtained from a sample from an irritable bowel disease patient; (f) immune cells are obtained from a peripheral blood sample and / or a tissue biopsy; (g) peripheral blood lymphocytes (PBLs) and / or T cells are obtained from the peripheral blood sample; (h) intraepithelial lymphocytes (IELs) are obtained from a tissue biopsy; (i) the immune cells are obtained from the same patient as the epithelial cells; (j) the immune cells are allogeneic to the organoids, and optionally the immune cells and the organoids are derived from either peripheral blood or tissue biopsies of different patients or healthy controls; (k) the immune cells are HLA-matched to the organoids; (l) the immune cells persist in immune cell growth medium for at least 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, and 240 hours; (m) at least one organoid comprises or consists of autologous cells; (n) at least one organoid is separated into populations sharing one or more genotypic, phenotypic, and / or epigenetic markers prior to mixing with the immune cells; and / or (o) genotypic, phenotypic, and / or epigenetic markers contribute to an interaction between (i) at least one organoid and (ii) an immune cell; 15. The method of any one of claims 1 to 14.
16. A method described in claim 15(n) or 15(o), wherein the populations share the presence or absence of an HLA haplotype, and optionally the HLA haplotype is HLA-A2.
17. (a) at least one organoid comprises or consists of mammalian cells, preferably human cells; (b) the organoid co-culture is cultured in immune cell growth medium or in a 50:50 (v / v) mixture of immune cell growth medium and organoid culture medium; and / or (c) the organoid co-culture is maintained in organoid co-culture medium or the reference organoid co-culture is maintained in organoid co-culture medium for at least 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, and 240 hours; 17. The method of any one of claims 1 to 16.
18. An organoid described in any one of claims 1 to 17, wherein the organoid is in a culture medium containing an interleukin, and optionally the interleukin is selected from the group consisting of IL-2, IL-7, and IL-15.
19. A population of organoids prepared according to the method of any one of claims 1 to 17.
20. An organoid co-culture and / or a reference organoid co-culture described in any one of claims 1 to 17.
21. The method of any one of claims 1 to 17, wherein the organoid culture medium comprises one or more (or preferably all) of a basic medium (such as Advanced DMEM / F12 medium, Gibco), a Wnt ligand (such as Wnt-3a), a Wnt agonist (such as any one of Rspondin 1-4), a BMP inhibitor (such as Noggin), EGF, and a TGF-β inhibitor (such as A83-01, Tocris), and optionally further comprises one or more (or all) of a p38 MAPK inhibitor, gastrin, nicotinamide, prostaglandin E, N-acetylcysteine, B27, and / or an antibacterial agent (such as Primocin).
22. (a) the immune cell growth medium comprises IL-2, optionally at a concentration of 2000-6000 IU / mL, and optionally further comprises IL-7 and / or IL-15; (b) preparing at least one organoid by culturing epithelial cells in an organoid culture medium comprising IL-2; (c) obtaining immune cells from an impure immune sample and preparing the immune cells by culturing the immune cells in an immune cell growth medium containing IL-2; (d) culturing the immune cells in an immune cell growth medium containing IL-2; (e) the immune cell growth medium further comprises RPMI medium (e.g., RPMI 1640, Gibco), optionally supplemented with penicillin / streptomycin and / or serum (e.g., 5% human AB serum, Sigma-Aldrich); and / or (f) the organoid co-culture medium contains IL-2, optionally at a concentration of 100-200 IU / mL; 22. The method of any one of claims 1 to 17 or 21.
23. A method for testing a CAR-T immunotherapy, a TCR transgenic T cell, a neoantigen, or a checkpoint inhibitor for efficacy and / or safety when used to treat irritable bowel disease, the method comprising: Optionally, providing epithelial cells, normal epithelial cells, and immune cells from the same patient; growing epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form an organoid co-culture; growing normal epithelial cells in organoid culture medium to form reference organoids and culturing the organoids with immune cells in organoid co-culture medium comprising an interleukin to form a reference organoid co-culture; contacting the organoid co-culture and the reference organoid co-culture with a CAR-T immunotherapy, a TCR transgenic T cell, a neoantigen, or a checkpoint inhibitor; detecting the presence or absence of one or more alterations in the organoid co-culture and the reference organoid co-culture, wherein the presence or absence of the one or more alterations indicates efficacy and / or safety of the CAR-T immunotherapy, TCR transgenic T cells, neoantigen, or checkpoint inhibitor; and Comparing the organoid co-culture and the reference organoid co-culture.
24. A method for testing a candidate compound for efficacy and / or safety for use in treating irritable bowel disease, the method comprising: Optionally, providing epithelial cells, normal epithelial cells, and immune cells from the same patient; growing epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form an organoid co-culture; Proliferating normal epithelial cells in organoid culture medium to form organoids and culturing the organoids with immune cells in organoid co-culture medium containing an interleukin to form a reference organoid co-culture; contacting the organoid co-culture and the reference organoid co-culture with a candidate compound; Detecting the presence or absence of one or more changes in the organoid co-culture and the reference organoid co-culture, wherein the presence or absence of the one or more changes indicates the efficacy and / or safety of the candidate compound; and Comparing the organoid co-culture and the reference organoid co-culture.
25. A method for preparing an organoid-immune cell co-culture, comprising: Optionally, culturing the epithelial cells in an organoid culture medium and in contact with an extracellular matrix to obtain organoids; Removing the extracellular matrix and organoid culture medium from the organoids; resuspending the organoids in immune cell culture medium supplemented with interleukins; preparing an immune cell suspension comprising immune cells, an immune cell culture medium supplemented with interleukins, and collagen at a concentration of at least 5-10% in the immune cell suspension; and Mixing the immune cell suspension containing the immune cells with the resuspended organoids.
26. (a) The collagen is rat tail collagen; (b) immune cell medium is RPMI1640 (Gibco); (c) the immune cell is a T cell; (d) the epithelial cells and the immune cells are obtained from the same subject, optionally from the same sample; and / or (e) the epithelial cells and immune cells are human cells; 26. The method of claim 25.
27. An organoid-immune cell co-culture obtained by the method described in any one of claims 25 to 26.
